

Golden Jubilee Year

50TH ANNUAL REPORT 2009-2010



ANUH PHARMA LIMITED



Mr. Ritesh Shah, General Manager - Marketing & Sales receiving the outstanding Export Performance Award from PHARMEXCIL for the year 2008-09 from the hands of Mr. Peter A. Nyongo, Hon. Minister for Medical Services, Government of Kenya, in the presence of Hon. Commerce Minister Shri Anand Sharma and Shri Bipin Shah, Managing Director of Anuh Pharma Limited.

ANUH PHARMA LTD.: A JOURNEY OF FIFTY YEARS....And many more to go!



SEVANTILAL K. SHAH

Birth : 14th November 1914 Died : 15th April 1979

*Fifty years ago, in the 1960s, when Shri P. R. Subramaniam, the then Chairman of Anuh Pharma Ltd. registered the company, it was with an idea to start a few Ayurvedic formulations. **Shri S.K. Shah**, founder Chairman of SK Group, was also one of the founder Directors of Anuh Pharma Ltd. Rudanil, Ugratin and Darnison were few of the ayurvedic formulations that Anuh Pharma started off with.*

However, our story is that of a magnificent metamorphosis. In the 1980s, the Sevantilal Kantilal Group acquired majority of the shares of Anuh Pharma Ltd. By 7th March, 1989, we shifted the location to a state of the art factory at MIDC, Tarapur. Today it stands there with six new plants added to the original construction.

There was also a major shift in the activities of the company. It has emerged as one of the largest producer of Erythromycins and various other Active Pharmaceutical Ingredients with a top line of 165 crores and reserves of more than 50 crores.

We have over a 100 dedicated staff and workmen who work relentlessly to keep the company soaring to greater heights. The company is a recipient of the Best Exporters Award, three times from Ministry of Commerce, Government of India. It has also received regulatory approval from European Directorate for the Quality of Medicines & Healthcare (EDQM) in form of Certificate of Suitability for Erythromycin Base, Erythromycin Ethyl Succinate, Pyrazinamide and Clobetalsol Propionate.

One share worth Rs. 10 in 1989 has risen to 96 shares of Rs. 5 each in 2010, the approximate market value of which is Rs. 19,200.

We believe in rising above our laurels. The management has already made a blue print for the next five years and the company dreams of achieving 400+ crores as top line to become one of the major players in production of pharmaceutical bulk drugs.

We are ready to fly higher with a brilliant past behind us and a wonderful future ahead!

ANUH PHARMA LTD.

Fiftieth Annual Report of the Board of Directors
with the Audited Statement of Accounts for the year ended 31st March, 2010

Board of Directors	: Mr. J. P. Shah, Chairman Mr. Bipin N. Shah, Managing Director Mr. L. P. Shah Mr. Bharat N. Shah Mr. J. G. Shah Mr. Dilip G. Shah Mr. Arun Todarwal Mr. Ashwin Shroff, Additional Director.
Auditors	: M/s. S. I. MOGUL & CO. Chartered Accountants Mumbai
Bankers	: BANK OF INDIA
Registrars and Transfer Agents	: BIGSHARE SERVICES PVT. LTD. E-2/3 Ansa Industrial Estate, Sakivihar Road, Saki Naka, Andheri (East), Mumbai 400 072 Tel: (022) 2847 0652 / 53
Registered Office	: 3-A Shiv Sasgar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai 400 018 Tel : (022) 6622 7575
Factory	: E-17/3 & 17/4 M.I.D.C., Tarapur, Boisar, Dist. Thane – 401 506

NOTICE

FIFTIETH ANNUAL GENERAL MEETING of the Members of ANUH PHARMA LIMITED will be held at 11.30 a.m. on Friday, 17th September, 2010, at M. C. Ghia Hall, 2nd Floor, Bhogilal Hargovindas Road, 18/20 K. Dubash Marg, Mumbai 400 001 to transact the following business :

ORDINARY BUSINESS

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2010 and the Profit & Loss Account for the year ended on that date and the Reports of the Directors and Auditors.
2. To confirm payment of Interim Dividend made by the Directors on the equity shares for the year ended 31st March, 2010 as final Dividend.
3. To appoint a Director in place of Mr. Jayantilal P. Shah who retires by rotation and, being eligible offers himself for re-appointment.
4. To appoint a Director in place of Mr. Bharat N. Shah who retires by rotation and, being eligible offers himself for re-appointment.
5. To appoint the auditors of the company and to fix their remuneration.

SPECIAL BUSINESS :

6. To consider and, if thought fit, to pass, with or without modification, as an Ordinary Resolution, the following :
"RESOLVED THAT Mr. Ashwin Shroff, who was appointed as an Additional Director of the company by the Board of Directors pursuant to Section 260 of the Companies Act, 1956 and Article 137 of the Articles of Association of the Company and who holds office upto the date of the ensuing Annual General Meeting and being eligible for re-appointment and in respect of whom the Company has received a notice in writing pursuant to the provisions of Section 257 of the Companies Act, 1956, proposing his candidature as a Director of the Company, be and is hereby appointed as a Director of the Company, whose period of office shall be liable to determination by retirement of Directors by rotation."
7. To consider and, if thought fit, to pass, with or without modification, as an Special Resolution, the following :
"RESOLVED THAT pursuant to Section 314 (1B) and other applicable provisions, if any, of the Companies Act, 1956, and subject to the approval of the Central Government, the consent of the company be and is hereby accorded to increase the remuneration payable to Mr. Ritesh B. Shah (General Manager - Marketing & Sales), effective from April 1, 2010, from existing Rs. 50,000/- per month to a sum to be fixed by the Board from time to time, not exceeding Rs. 2,00,000/- per month including bonus, contribution to statutory provident fund and other perquisites.
RESOLVED FURTHER THAT the Board of Directors be and are hereby authorised to take necessary steps in this regard."
8. To consider and, if thought fit, to pass, with or without modification, as an Special Resolution, the following :
"RESOLVED THAT pursuant to Section 314 (1B) and other applicable provisions, if any, of the Companies Act, 1956, and subject to the approval of the Central Government, the consent of the company be and is hereby accorded to increase the remuneration payable to Mr. Vivek B. Shah (General Manager - Works), effective from April 1, 2010, from existing Rs. 50,000/- per month to a sum to be fixed by the Board from time to time, not exceeding Rs. 1,50,000/- per month including bonus, contribution to statutory provident fund and other perquisites.
RESOLVED FURTHER THAT the Board of Directors be and are hereby authorised to take necessary steps in this regard."
9. To consider and, if thought fit, to pass, with or without modification, as a Special Resolution, the following :
"RESOLVED THAT pursuant to the provisions of the Companies Act, 1956 the approval of members be and is hereby granted to capitalize a sum of Rs. 2,78,40,000/- (Rupees Two crore seventy eight lakhs forty thousand only) out of the reserves set free for distribution amongst the equity shareholders by issue of 55,68,000 equity shares of Rs. 5/- (Rupees Five Only) each credited as fully paid to the equity shareholders in the proportion of Two equity shares for every One equity share held by them as on the record date, to be fixed by the Board.

RESOLVED FURTHER THAT the bonus shares to be issued as fully paid equity shares shall be subject to the Memorandum and Articles of Association of the Company ranking in all respects *pari passu* to the existing equity shares.

RESOLVED FURTHER THAT the Boards of Directors of the Company be and are hereby authorised to carry out the necessary formalities to give effect to the above resolution."

For and on behalf of the Board of Directors

Sd/-

J. P. SHAH
Chairman

Registered Office:

3-A, Shiv Sagar Estate,
Dr. Annie Besant Road,
Worli, Mumbai – 400 018

Place: Mumbai

Date: 6th August, 2010

NOTES :

1. The Register of Members and Share Transfer Book of the Company shall remain closed from 13th September, 2010 to 17th September, 2010 (both days inclusive)
2. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT ONE OR MORE PROXIES TO ATTEND AND, ON A POLL, TO VOTE INSTEAD OF HIMSELF. A PROXY NEED NOT BE A MEMBER. PROXIES IN ORDER TO BE EFFECTIVE MUST BE RECEIVED BY THE COMPANY NOT LESS THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING.
3. Members desirous of asking any questions at the Annual General Meeting are requested to send in their questions so as to reach the Company at least 7 days before the Annual General Meeting so that the same can be suitably replied.
4. Those Members who have so far not encashed their Dividend Warrants for earlier financial years may claim or approach the Company for payment, otherwise, the same will be transferred to the notified Fund as per the provision of Section 205 of the Companies Act, 1956.
5. Members are requested to notify change in address, if any, immediately to the Company at its Registered Office, quoting their Folio Numbers.
6. The relative Explanatory Statement, pursuant to Section 173(2) in respect of the special business set out in the accompanying Notice is annexed hereto.

EXPLANATORY STATEMENT UNDER SECTION 173 (2) OF THE COMPANIES ACT, 1956.

Item No. 6

Mr. Ashwin Shroff was appointed as an Additional Director of the company with effect from 30th October, 2009 under Article 137 of the Articles of Association of the Company. As per the provisions of Section 260 of the Companies Act, 1956, Mr. Ashwin Shroff holds office as a Director upto the date of the ensuing Annual General Meeting of the Company.

A notice in writing has been received from a member of the Company under Section 257 of the Companies Act, 1956 signifying his intention to propose Mr. Ashwin Shroff as a candidate for the office of Director of the Company. The requisite sum of Rs. 500/- as a deposit has been duly received from the member.

The Board recommends his appointment.

None of the Directors except Mr. Ashwin Shroff are, in any way, concerned or interested in the resolution.

Item No. 7

Mr. Ritesh B. Shah, who is the son of Mr. Bipin Shah, Managing Director, has been working as a Sales Executive of the company since 19th August, 2004. Looking to his excellent performance, effective from 1st April, 2010, he has been promoted to the position of General Manager - Marketing & Sales. In the Board Meeting of the company held on 6th August, 2010 the Board had approved his remuneration not exceeding Rs. 2,00,000/- per month effective from 1st April, 2010. In the Annual General Meeting of the company held on 29th September, 2007, the members had approved his remuneration to be fixed by the Board from time to time not exceeding Rs. 50,000/- including bonus, contribution to statutory provident fund and other perquisites, effective from 1st April, 2007.

The performance of Mr. Ritesh B. Shah, who is a MBA (USA) has been excellent and he has made significant contribution to the sales performance of the company. The Board in appreciation of his service, considers it appropriate to raise the remuneration payable to him, to be fixed by the Board from time to time, not exceeding Rs. 2,00,000/- per month including bonus, contribution to statutory provident fund and other perquisites, which is to be effective from 1st April, 2010.

As per provisions of Section 314(1B) of the Companies Act, 1956, such increase in remuneration is required to be approved by the members in a General Meeting through a Special Resolution.

The Board recommend the passing of the Special Resolution as set out at Item No. 7 of the accompanying Notice.

Mr. Bharat N. Shah and Mr. Bipin N. Shah are interested or concerned in the said Special Resolution.

Item No. 8

Mr. Vivek B. Shah, who is the son of Mr. Bipin Shah, Managing Director, has been working as a Sales Executive of the company since 1st October, 2008. Subsequently he was transferred to Tarapur plant to look after the production management of the factory. He has been working very hard and due to his commendable performance, effective from 1st April, 2010, he has been promoted to the position of General Manager - Works. In the Board Meeting of the company held on 6th August, 2010 the Board had approved his remuneration not exceeding Rs. 1,50,000/- per month effective from 1st April, 2010. In the Annual General Meeting of the company held on 16th September, 2009, the members had approved his remuneration to be fixed by the Board from time to time not exceeding Rs. 50,000/- including bonus, contribution to statutory provident fund and other perquisites, effective from 1st April, 2009.

The performance of Mr. Vivek B. Shah, who has done M.Sc. in Biotechnology has been excellent and he has made significant contribution to the production management at the company's plant. The Board in appreciation of his service, considers it appropriate to raise the remuneration payable to him, to be fixed by the Board from time to time, not exceeding Rs. 1,50,000/- per month including bonus, contribution to statutory provident fund and other perquisites, which is to be effective from 1st April, 2010.

As per provisions of Section 314(1B) of the Companies Act, 1956, such increase in remuneration is required to be approved by the members in a General Meeting through a Special Resolution.

The Board recommend the passing of the Special Resolution as set out at Item No. 8 of the accompanying Notice.

Mr. Bharat N. Shah and Mr. Bipin N. Shah are interested or concerned in the said Special Resolution.

Item No. 9

The year 2009-10 being the Golden Jubilee year of the company, to make it a memorable occasion, the Board of the Company proposes to issue Bonus shares in the ratio of 2 equity shares of Rs. 5/- each (fully paid) for every 1 equity share of Rs. 5/- each held. The company has ample Reserves to capitalize the same pursuant to provision of Section 81 of the Companies Act, 1956.

None of the Directors are concerned or interested in the Resolution except to the extent of their respective shareholdings.

For and on behalf of the Board of Director

Sd/-

J. P. SHAH
Chairman

Place: Mumbai
Date: 6th August, 2010

DIRECTORS' REPORT

The Members,

Your directors have pleasure in placing before you the 50th Annual Report of the Company along with the Accounts for the year ended 31st March, 2010:

FINANCIAL HIGHLIGHTS

Accounting Year	(Rupees in Lakhs)	
	2009-2010	2008-2009
Sales	16457	12051
Other Income	866	175
Profit before interest, depreciation and taxation	1881	1520
Interest	11	83
Depreciation	116	112
Provision for taxation (net)	469	425
Profit after tax	1285	900
Profit and Loss Account balance B/f	418	342
Profit available for Appropriation	1703	1242
Transfer to General Reserve	500	450
Proposed Dividend/Interim Dividend	279	320
Tax on Dividend	47	54
Balance carried to the Balance Sheet	877	418

DIVIDEND

Yours Directors recommend that the Interim Dividend of Rs. 10/- per share of face value of Rs. 5/- (200%) declared on 29th January, 2010 is to be treated as the final Dividend for the year ended 31st March, 2010.

BONUS SHARES

On the occasion of the Golden Jubilee Year of the Company, your Directors are pleased to propose issue of Bonus Shares in the ratio 1:2, thus capitalizing a sum of Rs. 2,78,40,000/- out of General Reserve.

OPERATIONS

The sales and operating income for the year ended 31st March, 2010 amounted to Rs. 16,457.22 lakhs as against Rs. 12,051.35 lakhs for the previous year. Thus the turnover of the company has increased by about 36.55% as compared to last year's turnover.

During the year 2009-10 profit before tax as compared to last year has increased by 32.29% from Rs. 1,325.48 lakhs to Rs. 1,753.52 lakhs and profit after tax has increased by 43.94% from Rs. 871.63 lakhs to Rs. 1,254.66 lakhs.

EXPORTS

Exports for the year ended 31st March, 2010 have increased by about 11.92% from Rs. 5,641.13 lakhs to Rs. 6,313.88 lakhs.

CURRENT OUTLOOK

The company expects to maintain the tempo of growth during the current year as well, and may achieve record sales and net profit.

DIRECTORS

Mr. Ashwin Shroff was appointed as an Additional Director on the Board with effect from October 30, 2009. Mr. Ashwin Shroff holds office as a Director upto the date of the ensuing Annual General Meeting of the Company, a notice in writing under Section 257 of the Companies Act, 1956 has been received by the Company to appoint Ashwin Shroff as a Director of the Company.

Mr. Jayantilal P. Shah and Mr. Bharat N. Shah retire by rotation at the forthcoming Annual General Meeting and being eligible have offered himself for re-appointment.

LISTING ON THE STOCK EXCHANGES

The Company's shares are listed with Bombay Stock Exchange Ltd. and the Company has paid the necessary listing fees for the Financial Year 2010-11.

FIXED DEPOSITS

The Company has not accepted or renewed any Fixed Deposits within the meaning of Section 58-A of the Companies Act, 1956.

PARTICULARS OF EMPLOYEES

In terms of the provisions of Section 217(2A) of the Companies Act, 1956, read with the Companies (Particulars of Employees) Rules, 1975 as amended, the names and other particulars of the employees are set out in the annexure to the Directors' Report. However, having regard to the provisions of Section 219(1)(b)(iv) of the said Act, the Annual Report excluding the aforesaid information is being sent to all members of the Company and others entitled thereto. Any member interested in obtaining such particulars may write to the Company at the registered office of the Company.

DIRECTORS' RESPONSIBILITY STATEMENT

The Directors confirm that in the preparation of the annual accounts for the year ended 31st March, 2010:-

- i) The applicable accounting standards have been followed along with proper explanations relating to material departures, if any.
- ii) That the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year viz. 31st March, 2010 and of the profit or loss of the Company for the year ended on that date.
- iii) That the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- iv) That the directors had prepared the annual accounts on a going concern basis.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO {SECTION 217 (1)(E)}

As required under Rule 2 of the Companies (Disclosure of Particulars in the report of Board of Directors) Rules, 1988 the particulars relating to conservation of energy, technology absorption, foreign exchange earnings and outgo are given in Annexure 'A' and forming part of this report.

SECRETARIAL COMPLIANCE REPORT

Your company has appointed M/s. Sanjay Doshi & Associates, Company Secretaries, to certify the compliance of the Companies Act requirements observed by us. A copy of their Certificate is attached.

AUDITORS

M/s. S. I. Mogul & Co., Chartered Accountants, the Statutory Auditors of the Company retire at this Annual General Meeting and are eligible for the re-appointment as Auditors of the company to hold the office from the date of this Annual General Meeting until the conclusion of the next Annual General Meeting. The Directors recommend reappointing M/s. S. I. Mogul & Co., as auditors of the company. A certificate has been received from the Auditors to the effect that their re-appointment, if made, would be within the prescribed limits u/s. 224 (1B) of the Companies Act, 1956.

ACKNOWLEDGEMENT

Your directors would like to express their sincere appreciation for the assistance and cooperation received from our bankers, employees, auditors and consultants during the period under review. The Directors sincerely appreciate the high degree of professionalism, commitment and dedication displayed by employees at all levels. The Directors also place on record their gratitude to the Members for their continued support and confidence.

By Order of the Board

Sd/-

J. P. SHAH
Chairman

Registered Office:

3-A, Shiv Sagar Estate,
Dr. Annie Besant Road,
Worli, Mumbai - 400 018

Place: Mumbai.

Date: 6th August, 2010



ANNEXURE 'A' TO THE DIRECTORS' REPORT

(Under Section 217(1)(e) of the Companies Act, 1956)

1. CONSERVATION OF ENERGY

Form for Disclosure of Particulars with respect to Conservation of Energy.

A. Power and fuel consumption:

	Current Year 2009-10	Previous Year 2008-09
1. Electricity		
(a) Purchased		
Units	1929055	1560560
Total amount (Rs. In lacs)	98.75	71.46
Rate/unit (Rs.)	5.12	4.58
(b) Own generation		
Rate/Unit (Rs.)	Nil	Nil
2. Coal	Nil	Nil
3. Light Diesel Oil		
Quantity (KL)	105.47	77.65
Total cost (Rs. In lacs)	36.46	29.31
Average rate per ltr. (Rs.)	34.57	37.75
4. Other/Internal generation	N.A.	N.A.
B. Consumption per unit of production		
Electricity KWH	3.80	3.96
Light Diesel Oil Ltrs.	0.21	0.20
Coal	N.A.	N.A.
Other	N.A.	N.A.

2. TECHNOLOGY ABSORPTION

A. Research & Development (R&D)	Nil	Nil
B. Technology absorption, adoption and innovation	Nil	Nil

3. FOREIGN EXCHANGE EARNINGS AND OUTGO

- A. **Earnings:** The FOB value of export of the company during the year aggregated to Rs. 6,226.50 lakhs as against Rs. 5,349.98 lakhs in the previous year.
- B. **Outgo:** The CIF value of outgo in foreign exchange of the company by way of imports, payment of commission, exhibition and travelling expenses aggregated to Rs. 12,903.30 lakhs during the year as against Rs. 8,022.86 lakhs in the previous year.

COMPLIANCE CERTIFICATE

CIN of the Company: L24230MH1960PLC011586

Nominal Capital: Rs. 100,000,000/-

The Members,
ANUH PHARMA LIMITED
 A-3, Shiv Sagar Estate, North Wing,
 Dr. Annie Besant Road,
 Worli, Mumbai - 400 018.

We have examined the registers, records, books and papers of **ANUH PHARMA LIMITED** as required to be maintained under the Companies Act, 1956, (the Act) and the rules made thereunder and also the provisions contained in the Memorandum and Articles of Association of the Company for the financial year ended on **31st March, 2010**. In our opinion and to the best of our information and according to the examinations carried out by us and explanations furnished to me/us by the company, its officers and agents, we certify that in respect of the aforesaid financial year:

1. The Company has kept and maintained all registers as stated in **Annexure 'A'** to this certificate, as per provisions and the rules made thereunder and all entries therein have been duly recorded.
2. The Company has duly filed the forms and returns as stated in **Annexure 'B'** to this certificate, with the Registrar of Companies, Regional Director, Central Government, Company Law Board or other authorities within the time prescribed under the act and the rules made thereunder.
3. The Company, being Public Limited Company, comments under Section 3(1)(iii) of the Companies Act, 1956, applicable to a private company are not required.
4. The Board of Directors duly met **4 times** on **29th April, 2009, 31st July, 2009, 30th October, 2009** and **29th January, 2010** in respect of which meetings proper notices were given and the proceedings were properly signed and recorded in the Minutes Book maintained for the purpose.
5. The Company has closed its Register of Members from **11th September, 2009 to 16th September, 2009 (both days inclusive)** and necessary compliance of Section 154 of the Act has been made.
6. The Annual General Meeting for the financial year ended on **31st March, 2009** was held on **16th September, 2009** after giving due notice to the Members of the Company and the resolution passed thereat were duly recorded in the Minutes Book maintained for the purpose.
7. No Extra Ordinary General Meeting was held during the financial year.
8. The Company has not advanced any loans to its directors and/or persons or firms referred in the Section 295.
9. The Company has duly complied with the provisions of the Section 297 of the Act in respect of contracts specified in that section during the year under scrutiny.
10. The Company has made necessary entries in the register maintained under Section 301 of the Act.
11. The Company has obtained necessary approvals from the Members as required pursuant to the provisions of Section 314 of the Act wherever applicable.
12. The Company has not issued any duplicate share certificates during the financial year.
13. The Company:
 - (i) Has made no allotment during the F.Y. 2009-2010 and has delivered all the certificates on lodgement thereof for transfer / transmission or any other purpose during the F.Y. 2009-2010 in accordance with the provisions of the Act.
 - (ii) (a) has deposited the amount of final dividend declared on **16th September, 2009** in a separate Bank Account on **18th September, 2009** which is within 5 days from the date of declaration of such dividend.
 (b) has deposited the interim dividend declared on **29th January, 2010** in a separate Bank Account on **9th February, 2010**.
 - (iii) has paid / posted warrants for the dividend declared to all the members within a period of 30 (Thirty) days from the date of declaration.

- (iv) has transferred the amounts from Dividend Account, which have remained unclaimed / unpaid for a period of seven years to Investor Education and Protection Fund for the dividend declared for the year ended **2001-2002** during the Financial Year **2009-2010**.
- (v) has duly complied with the requirements of Section 217 of the Act.
14. The Board of Directors of the Company is duly constituted and the appointment of directors, additional directors and directors to fill casual vacancies have been made, as applicable;
 15. The Company has re-appointed Managing Director during the financial year under scrutiny.
 16. The Company has not appointed any sole-selling agents during the financial year.
 17. The Company was not required to obtain any approvals of the Central Government, Company Law Board, Regional Director, Registrar and/or such authorities prescribed under the various provisions of the Act during the financial year.
 18. The Directors have disclosed their interest in other firms / companies to the Board of Directors pursuant to the provisions of the Act and the rules made thereunder.
 19. The Company has not issued any Equity Shares during the F.Y. ending on 31st March, 2010.
 20. The Company has not bought back any shares during the financial year ending on 31st March, 2010.
 21. The Company has no preference shares / debentures.
 22. There were no transactions necessitating the company to keep in abeyance the rights to dividend, rights shares and bonus shares pending registration of transfer of shares.
 23. The Company has not invited / accepted any deposits including any unsecured loans falling within the purview of Section 58A the financial year.
 24. The amount borrowed by the company from directors, members, public, financial institutions, banks and others during the financial year ending **31st March, 2010** is within the borrowing limits of the company.
 25. The Company has made loans and investments, or given guarantees or provided securities to other bodies corporate in compliance with the provisions of the Act.
 26. The Company has not altered the provisions of the Memorandum with respect to situation of the company's registered office from one state to another during the year under review.
 27. The Company has not altered the provisions of the Memorandum with respect to the objects of the company during the year under scrutiny.
 28. The Company has not altered the provisions of the Memorandum with respect to the name of the company during the year under scrutiny.
 29. The Company has altered the provisions of the Memorandum with respect to the share capital of the company during the year under scrutiny and complied with the provisions of the Act.
 30. The Company has altered its Articles of Association during the year under scrutiny.
 31. There were no prosecution initiated against the Company and no fines or penalties or any other punishment was imposed on the company during the financial year for offences under the Companies Act.
 32. The Company has not received any money as security from its employees during the Financial Year.
 33. As informed to us, the Provident Fund contribution has been deposited regularly during the year with the prescribed authorities.

For Sanjay Doshi & Associates
Company Secretaries

Sd/-

SANJAY DOSHI
Proprietor
C.P. No.: 7595

Place : Mumbai
Date : 6th August, 2010

ANNEXURE A
Registers maintained by the Company :

Particulars	Under Section
1. Register of Members	u/s 150.
2. Register of Transfers	–
3. Books of Accounts	u/s 209.
4. Register of Particulars of Contracts in which Directors are interested	u/s 301
5. Register of Proxies	–
6. Register of Directors, Managing Directors, u/s 303 Manager & Secretary	u/s 303
7. Register of Directors Shareholdings	u/s 307
8. Register of Charges	u/s 143
9. Index of Members	u/s 151
10. Register of Directors' Attendance	–
11. Register of Shareholders' Attendance	–
12. Register of Fixed Assets	–
13. Minutes Book of Board & General Meeting	u/s 193

ANNEXURE B
Forms and returns as filed by the Company with the Registrar of Companies, Regional Director, Central Government or other authorities during the financial year ending on 31st March, 2010.

Sr. No.	Form No./ Return	Filed under Section	For	Date of Filing	Whether filed within prescribed time Yes / No	If delay in filing whether requisite additional fee paid Yes / No
1.	Form 20B	Sec.159	Annual Return	05.11.2009	Yes	N.A.
2.	Form 23AC & 23ACA	Sec. 210 & 220	Balance Sheet as on 31.03.2009	10.10.2009	Yes	N.A.
3.	Form 66	Sec.383A	Compliance Certificate	10.10.2009	Yes	N.A.
4.	Form 32	Sec. 303	Change in Director	04.08.2009	No	Yes.
5.	Form 32	Sec. 303	Change in Director	08.10.2009	Yes	N.A.
6.	Form 32	Sec. 303	Change in Director	13.11.2009	Yes	N.A.
7.	Form 23	Sec. 192	Registration of resolution	26.05.2009	Yes	N.A.
8.	Form 25C	Sec. 269	Appointment of Managing Director	26.05.2009	Yes	N.A.
9.	Form 23	Sec. 192	Registration of resolution	08.10.2009	Yes	N.A.
10.	Form 5	Sec. 94 & 16	Increase in Authorised Capital	09.10.2009	Yes	N.A.
11.	1 INV	Rule 3 of Investor Education & Protection Fund (Awareness & Protection of Investors) Rules, 2001	Amount credited to Investor Education & Protection Fund	08.10.2009	Yes	N.A.

MANAGEMENT DISCUSSION AND ANALYSIS

GLOBAL PHARMACEUTICAL MARKET

The global pharmaceutical industry grew up by 10% in 2008 (Source: imsorg report). The growth was attributed to the economic, structural, political and health dynamics across the countries. At present, the growth and market potential is shifting from matured to emerging markets.

The regulatory and non-regulated markets of pharmaceuticals are looking at reducing their costs to keep pace with competition and recession.

INDIAN PHARMACEUTICAL MARKET

The Indian pharmaceutical sector is growing at a very rapid pace. Today, India is recognized as one of the leading global players in the pharmaceutical industry.

It is estimated that by 2,014, the Indian pharmaceutical industry will be able to achieve sales turnover of over Rs. 1,00,000 crores in formulations and bulk drug production. Exhibiting a consistent growth of 9.5% for the last five years, Indian pharmaceutical industry is expected to have a growth rate of 13.6% by 2010.

The bulk raw materials from India are getting very popular and many plants have received US FDA and EDQM approvals.

MANUFACTURING

Anuh Pharma Ltd. is well positioned to service its existing and potential markets through its manufacturing operations at Tarapur in Maharashtra.

The company enjoys WHO GMP and ISO 9001:2008 approvals and all the facilities are built and operated according to cGMP (current good manufacturing practices).

The company has also submitted DMF to USFDA and EDQM authorities have issued Certificate of Suitability (COS) for (1) ERYTHROMYCIN BASE, (2) ERYTHROMYCIN ETHYL SUCCINATE, (3) PYRAZINAMIDE and (4) CLOBETASOL PROPIONATE.

The company has also received plant approvals from several MNCs.

We had further undertaken expansion of our plant capacity and it was commissioned in September 2008.

QUALITY

Quality is the key factor for any API business and Anuh Pharma Ltd. embodies a high reputation for quality. An array of quality control tests conducted with the latest laboratory testing equipments covers the company's entire production processes. We have added a number of sophisticated instruments like HPLC, GC, etc.

RESEARCH & DEVELOPMENT

Anuh Pharma Ltd. is leveraging on its strong R&D foundations and is looking towards exploiting the niche products segment in as many markets as possible.

The company's focus is to develop multi step non-infringing processes for generic APIs that are novel to the Indian and International markets. During the year we have developed process for 2 generic APIs.

HUMAN RESOURCES

Anuh Pharma Ltd. has always acknowledged its human capital as the most important and fundamental source of its success. Consequently, a steady and well managed HR department heads the company and has enabled it to acquire, develop, motivate and maintain its skilled human resource.

The company worked on its recruitment process at bringing about improvement in:

1. Speed at which talent is brought in.
2. Quality of talent with respect to competence and compatibility.
3. Cost of recruitment.

FINANCIAL PERFORMANCE

In the bygone fiscal, the sales of Anuh Pharma Ltd. increased by 36.55% to Rs. 16,457.22 lakhs from Rs. 12,051.35 lakhs.

The company generated Rs. 1,753.52 lakhs in net profit after extraordinary items as compared to Rs. 1325.48 lakhs in the previous year.

OPPORTUNITIES AND OUTLOOK

Anuh Pharma Ltd. will be able to place itself in a strong position by expanding strategically, increasing its manufacturing capacities and enhancing capacities across the organization.

The company is looking at different opportunities in untapped markets and also across a value chain. It plans for alliances with business associates in the global market, giving a huge boost to the selective products that it already deals in.

We are fully conscious of our responsibility toward our customers. Our efforts are directed toward the fulfillment of customer satisfaction through the quality of products. As the consolidation of this industry gains momentum, the need to develop a dedicated team of skilled manpower assumes urgency and importance.

We will continue to focus on training and motivation of manpower so as to develop teams of qualified and skilled personnel to effectively discharge their responsibilities in a number of projects and activities. It is, in this context, which we have been working towards promoting the skills and professionalism of our employees to cope with and focus on the challenges of change and growth.

CAUTIONARY STATEMENT

Certain statement in the management discussion and analysis may be forward looking within the meaning of applicable securities law and regulations and actual results may differ materially from those expressed or implied. Factors that would make differences to Company's operations include competition, price realisation, forex market, changes in government policies and regulations, tax regimes, economic development within India and the countries in which the Company conducts business and other incidental factors.

CORPORATE GOVERNANCE REPORT

Pursuant to Clause 49 of the Listing Agreement following is the report on Corporate Governance for the financial year 2009-10.

Company's Philosophy on Code of Corporate Governance

The Company believes that Corporate Governance envisages attainment of high level of transparency, accountability, fair and equal treatment of all shareholders, compliance with regulations, and sustainable value creation for all shareholders, ethical practices and integrity thereby assisting the top management of the Company in efficient conduct of its business.

The Company believes that its systems and actions must be integrated for enhancement of corporate performance resulting in maximization of shareholders' value in the long run, protection of the interest of its shareholders and employees and maintenance of cordial relationship with its customers and bankers. The Company places due emphasis on regulatory compliances.

I. BOARD OF DIRECTORS

(A) Composition of Board and changes since the date of last Annual General Meeting

The present Board of Directors of the Company comprises of 8 Directors, of which 1 is Executive Director, 3 are Non-Executive Directors and remaining 4 are Independent Non-Executive Directors with independent judgment in the deliberation and decision of the Board. The Chairman of the Board is a Non-Executive Director.

Changes since last AGM

Shri Ashwin Shroff was appointed as an additional Independent Non-Executive Director on October 30, 2009.

(B) No. of Board Meetings

The Board of Directors met 4 times during the year under review. The meetings of the Board of Directors were held on various dates as follows:

(1) April 29, 2009 (2) July 31, 2009 (3) October 30, 2009 and (4) January 29, 2010. Detailed agenda notes and the information required to be given in terms of Business on the agenda were circulated in advance to all the Directors of the Company. The Directors including Non-Executive Directors actively participated in the Board Meetings.

Name of the Director	Designation	Category	No. of Board Meetings held during the year	No. of Board Meetings attended during the year	Attendance at last AGM Held on September 16, 2009
Shri J. P. Shah	Chairman	Promoter Non-Executive Director	4	3	Yes
Shri Bipin N. Shah	Managing Director	Promoter Executive Director	4	4	Yes
Shri L. P. Shah	Director	Promoter Non-Executive Director	4	4	Yes
Shri Bharat N. Shah	Director	Promoter Non-Executive Director	4	4	Yes
Shri J. G. Shah	Director	Independent Non-Executive Director	4	3	Yes
Shri Dilip G. Shah	Director	Independent Non-Executive Director	4	2	No
Shri Arun Todarwal	Director	Independent Non-Executive Director	4	3	Yes
*Shri Ashwin Shroff	Additional Director	Independent Non-Executive Director	2	1	No
**Shri S. P. Sonawala	Director	Independent Non-Executive Director	1	1	No

* Shri Ashwin Shroff was appointed as an Additional Director with effect from October 30, 2009.

* * Shri S. P. Sonawala ceased to be a Director from 29th June, 2009 due to death.

(C) Secretarial Standards relating to the Meetings:

The Institute of Company Secretaries of India (ICSI) has established Secretarial Standards relating to the Meetings of the Board and Committees thereof and Annual General Meetings. At this stage, these are only recommendatory and are likely to become mandatory in due course. It is the intention of the Company to generally comply with these Standards.

At the end of the year, none of the Directors is a member of more than ten Board-level Committees or a Chairman of more than five such Committees, as required under Clause 49 of the Listing Agreement.

(D) Information required under Clause 49 IV(G) of the listing agreement on Directors seeking appointment / re-appointment :
Mr. J. P. Shah

Shri. J. P. Shah aged 81 years is a B.A. LL.B. and is a Non-Executive Director and Chairman of the Company since October 1980. He has over 60 years experience in managing pharmaceutical business and industry. He has been instrumental in setting up several business and pharmaceutical units of the SK Group.

He is also a Director in the following companies:

1. Sevantilal Kantilal Private Limited
2. Japoshia Investments Private Limited

In the past, he has held senior positions in business associations and social / educational organizations like:

- a. Member of the Managing Committee of Chemist & Druggists Association.
- b. Chairman of Patan Co-op. Bank Ltd.
- c. President of Rotary Club of Bombay South.
- d. Managing Committee Member of North Gujarat Education Society.

Mr. Bharat N. Shah

Mr. Bharat N. Shah aged 64 years, has a Diploma in Commerce and is a Non-Executive Director of the Company since October 1980. He has more than 40 years experience in managing pharmaceutical business and industry.

He is also a Director in the following companies :

1. S. Kant Healthcare Ltd.
2. Sevantilal Kantilal Pvt. Ltd.
3. S. Kant Chemicals Pvt. Ltd.
4. Sevak Pharma Pvt. Ltd.

He is also active in various business association and social / educational organization and presently is a office bearer in the following organizations :

1. Indian Drug Manufacturing Association
2. Indo Iran Chamber of Commerce & Industry
3. North Gujarat Education Society
4. Patan Jain Mandal

He was also the past President of Rotary Club of Mumbai Queen's Necklace.

He is also a Trustee of Sevantilal Kantilal Trust

Mr. Ashwin C. Shroff

Shri. Ashwin C. Shroff, aged 65 years, a graduate in Chemistry from Bombay University, joined Excel Industries Ltd. Moving through various operational and functional departments in the Company, he rose to become its Managing Director in 1995. He became the Chairman of the Company in 2004.

Along these crucial years of growth, both Excel Industries Ltd. and he have emerged stronger, revolutionizing the Industrial chemicals, Agro chemicals and Environment related businesses.

Mr. Ashwin Shroff has been a active spokesman of the Indian Chemical industry and, as the President of Indian Chemical Council (ICC) during 1996-98, he represented the industry at various levels. He has had the opportunity to interact with the Government bodies and share his experience in shaping the industry specific policies.

Mr. Ashwin Shroff has been a regular participant in various study groups, conferences, seminars etc., and has contributed papers on diverse subjects, and articles in leading journals.

Mr. Ashwin Shroff is connected with various NGOs like The Vivekanand Research & Training Institute (VRTI).

He is also a Director in the following companies:

1. Chairman & Managing Director of Excel Industries Ltd.
2. Chairman & Director of Excel Corp. Care Ltd., Mumbai
3. Chairman & Director of Transpek Industry Ltd., Baroda
4. Chairman & Director of Transpek - Silox Industry Ltd., Baroda
5. Director of Excel Industries (Australia) Pty. Ltd.
6. Director, Phthalo Colours & Chemicals (India) Ltd.
7. Director, Waxsam Limited, Hong Kong
8. ECCL Investments & Finance Limited
9. Director of Kamaljyot Investment Ltd.

In the past, he has held and presently also he holds senior positions in business associations and social/ educational organizations like:

- Past president of Indian Chemical Council
- Past Executive Committee Member, Kutchh Navnirman Abhiyan (a federation of Voluntary agencies in Kutchh)
- Trustee of Vivekanand Research & Training Institute (VRTI), a voluntary agency based in Kutchh, Gujarat
- Chairman, FICCI Environment Committee
- Committee Member, Ramkrishna Mission, Mumbai
- Also associated with Management Educational Institutes viz. SIES College of Management Studies (SIESCOM) and Narsee Monjee Institute of Management Studies (NMIMS)

REMUNERATION OF DIRECTORS

Details of Remuneration

The Board, within the overall limits approved by the Members, considered the matters with regard to review and approval of remuneration payable to the Executive and Non-Executive Directors of the Company. Details of remuneration to the directors of the Company for the year ended March 31, 2010 are as follows:

Name of Director	Sitting Fees (Rs.)	Salary & Perquisites (Rs.)	
Shri Bipin N. Shah	–	Salary & perquisites	14,67,718
		Commission	14,97,699
		Total	29,65,417
Shri J. P. Shah	15,500	–	
Shri Bharat N. Shah	20,000	–	
Shri Lalit P. Shah	20,000	–	
Shri J. G. Shah	31,000	–	
Shri S. P. Sonawala	9,000	–	
Shri Dilip G. Shah	31,000	–	
Shri Arun Todarwal	26,500	–	
Shri Ashwin Shroff	4,500	–	

II. AUDIT COMMITTEE

Terms of Reference & Composition, Name of Member and Chairman:

The Audit Committee of the Company comprises of Shri J. G. Shah, Chairman of the Committee, Shri Arun Todarwal and Shri Dilip G. Shah, all being Independent Directors and Shri Bipin N. Shah, who is the Managing Director of the company. All members of the Audit Committee have knowledge on financial matters and the Chairman of the Audit Committee was a Company Secretary in various large Indian and multi-national companies.

The Company has appointed M/s. I. O. Dharia & Co., Chartered Accountants, as Internal Auditors of the Company for reviewing with the management quarterly and annual financial statements and other matters as covered under Clause 49 of the Listing Agreement and report to the Audit Committee.

The terms of Reference to this Committee, *inter-alia*, covers all the matters, specified under Section 292(A) of the Companies Act, 1956 and also all the matters listed under Clause 49 of the Listing Agreement with the Stock Exchange such as oversight of the Company's financial reporting process; recommending the appointment / re-appointment of statutory auditors. The Audit Committee has powers, *inter-alia*, to investigate any activity within its terms of reference and to seek information from any employee of the company as well as seek outside legal and professional advice.

The Audit Committee reviews all the information that are required to be mandatorily reviewed by it under the corporate governance.

The Audit Committee met 4 times (Including one adjourned meeting) during the year under review. The meetings were held on various dates as follows:

- (1) April 28, 2009 (2) July 28, 2009, (3) October, 28, 2009 (4) January 27, 2010

The attendance of each member of Audit Committee in the committee meetings is given below :

Name of the Director	No. of Meeting Held	No. of Meeting attended
Shri J. G. Shah	4	3
Shri S. P. Sonawala*	4	1
Shri Arun Todarwal	4	1
Shri Bipin N. Shah	4	4
Shri Dilip G. Shah	4	4

* Shri S.P. Sonawala has ceased as a Director with effect from 29th June, 2009.

COMPANY SECRETARY

Since the Company's paid-up capital is less than Rs. 5,00,00,000/- (Rupees Five crores only) as per the provisions of Section 383A of the Companies Act, 1956 Company is not required to appoint full time Company Secretary in Employment but is required to obtain a Secretarial Compliance Certificate from Company Secretary in Practice. Company has obtained the required Certificate from M/s. Sanjay Doshi & Associates, Practicing Company Secretary.

III. SHARE TRANSFER CUM INVESTORS GRIEVANCE COMMITTEE

The Share Transfer cum Investors Grievance Committee consists of 3 Directors. Shri Lalit P. Shah, Shri Bharat N. Shah and Shri Bipin N. Shah. Shri Lalit P. Shah, Non-Executive Director, is the Chairman of the Committee. No transfers were pending as on March 31, 2010. The Company received 9 (Nine) complaints during the year under review and the same were resolved satisfactorily. No complaint was pending as on March 31, 2010.

The details of the last three Annual General Meetings held are as follows:

Year	Venue	Date	Time
2006-2007	M. C. Ghia Hall, 2nd Floor, Bhogilal Hargovindas Road, 18/20 K. Dubash Marg, Mumbai - 400 001.	29.09.2007	12.30 p.m.
2007-2008	Dahanukar Hall, 6th Floor, Oricon House, Maharashtra Chamber of Commerce Path, Fort, Mumbai – 400 001.	12.09.2008	11.30 a.m
2008-2009	M. C. Ghia Hall, 2nd Floor, Bhogilal Hargovindas Road, 18/20 K. Dubash Marg, Mumbai - 400 001.	16.09.2009	11.30 a.m.

DECLARATION

I, Bipin N. Shah, Managing Director of Anuh Pharma Limited, hereby declare that all the members of the Board of Directors and the Senior Management Personnel have affirmed compliance with the Code of Conduct, applicable to them as laid down by the Board of Directors in terms of Clause 49(1) (D) (ii) of the Listing Agreement entered into with the Stock Exchange for the year ended March 31, 2010.

MD / CEO CERTIFICATION

The Managing Director / CEO have certified to the Board, *inter alia* the accuracy of financial statements and adequacy of internal controls for the financial reporting purpose as required under Clause 49(v) of the Listing Agreement, for the year ended March 31, 2010.

DISCLOSURES

- Disclosures on materially significant related party transactions i.e. transactions of the Company of material nature, with its Promoters, the Directors or the Management, their subsidiaries or relatives etc. that may have potential conflict with the interests of the Company at large. Details are given elsewhere in the Annual Report at para. 10 of the Notes to Accounts (Schedule - 20).
- Details of non-compliance by the company, penalties, and strictures imposed on the Company by the Stock Exchanges or SEBI or any statutory authority, on any matter related to capital markets, during the last three years - NIL.

- Company has complied with all mandatory requirements of Clause 49 of the Listing Agreement in respect of Corporate Governance. The Company has not adopted a whistle blower policy, which is not a mandatory requirement as per the Listing Agreement.

MEANS OF COMMUNICATION

The quarterly / half-yearly / annual financial results are normally published in English and Marathi Newspapers viz. in Free Press Journal, and Navshakti, Mumbai respectively. A Report on Management Discussion and Analysis forms part of the Annual Report.

GENERAL SHAREHOLDER INFORMATION

A. Annual General Meeting

Day	: Friday
Date	: September 17, 2010
Time	: 11.30 a.m.
Venue	: 2nd Floor, M. C. Ghia Hall, Bhogilal Hargovindas Building, 18/20 K. Dubash Marg, Kala Ghoda, Mumbai 400 001

B. Financial Calendar

Quarter	Period	Publications of Results
First	Apr-Jun	1st August, 2009
Second	Jul-Sep	31st October, 2009
Third	Oct-Dec	2nd February, 2009
Fourth	Jan-Mar	21st April, 2010

C. Dates of Book Closure : Monday, 13th September, 2010 to 17th September, 2010

D. Dividend Payment Date : September 16, 2009 for F.Y. 2008-09 as Final Dividend and January 29, 2010 for F.Y. 2009-10 as Interim Dividend

E. Listing on Stock Exchanges : The Company's Equity Shares are listed on The Bombay Stock Exchange, Mumbai

F. Stock Code : 506260 on the Stock Exchange, Mumbai.

G. ISIN Number for NSDL & CDSL : INE489G01022

H. Market Price Data

High & Low during each month in the last financial year (given below) :

Month	High (Rs.)	Low (Rs.)
April 2009	180.00	137.00
May 2009	244.95	155.10
June 2009	249.00	193.10
July 2009	244.00	172.00
August 2009	375.00	230.20
September 2009	375.00	303.50
October 2009	342.00	311.00
November 2009	350.00	304.00
December 2009	369.00	310.00
January 2010	465.00	358.00
February 2010	465.30	370.00
March 2010	414.00	333.65

- I. Registrars & Transfer Agent** : Big Share Services Pvt. Limited
E-2/3, Ansa Industrial Estate,
Sakivihar Road, Sakinaka, Andheri (East),
Mumbai - 400 072
Tel: 022 28470652 / 53
- J. Share Transfer** : All transfers received are processed by the Share Transfer Agents and Share Transfer Register is sent to the Company for approval. The Share Transfer cum Investors / Shareholders' Grievance Committee comprising Directors considers and approves the same. Thereafter, the Share Transfer Agents carry out necessary endorsements on the share certificates and dispatch the same to the transferees.

K. Shareholding Pattern :

The Distribution of the shareholding pattern as on 31st March, 2010 was as under:

Category	No. of Shareholders	% of total Shareholders	No. of Shares held	% of Shareholding
Upto 5000	3,263	95.30	3,53,338	12.69
5001 - 10000	93	2.72	1,37,851	4.95
10001 - 20000	29	0.85	86,849	3.12
20001 - 30000	7	0.20	38,680	1.39
30001 - 40000	9	0.26	66,524	2.39
40001 - 50000	4	0.12	35,791	1.29
50001 - 100000	4	0.12	60,698	2.18
100001 and above	15	0.43	20,04,269	71.99
Total	3,424	100.00	27,84,000	100.00

Shareholding Pattern as on March 31, 2010

Category	No. of Shareholders	No. of Shares	% holding
Indian Promoters	27	1987601	71.39
Clearing Members	12	1234	0.04
FII's and NRIs	30	11700	0.42
Domestic Companies	123	75099	2.70
Resident Individuals	3232	708366	25.45
TOTAL	3424	2784000	100

Dematerialisation of Shares: 26,91,348 Equity Shares equivalent to 96.67% of the total paid-up Equity Capital have been in dematerialized form as on 31st March, 2010.

- Compliance Officer : Mr. G. J. Chari
E-Mail ID : anuh@sk1932.com
Tel.No. : 022 6622 7575
Fax No. : 022 6622 7600
Address for Correspondence : 3-A, Shiv Sagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai - 400 018.

CERTIFICATE ON CORPORATE GOVERNANCE

The Members of
ANUH PHARMA LIMITED

We have examined the compliances of conditions of Corporate Governance by "ANUH PHARMA LIMITED" (hereinafter referred to as the Company) for the year ended 31st March, 2010 as stipulated in Clause 49 of the Listing Agreement of the Company with the Stock Exchanges.

The compliance of conditions of Corporate Governance is the responsibility of the management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the condition of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us by the Management, we certify that the Company has complied with the conditions of the Corporate Governance as stipulated in the abovementioned Listing Agreements.

We state that no investor grievances are pending for a period exceeding one month against the Company as per the records maintained and produced before us by the Share Transfer-cum-Investors Grievance Committee.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the effectiveness with which the management has conducted the affairs of the Company.

Place : Mumbai
Date : 6th August, 2010

For Sanjay Doshi & Associates
Company Secretaries

Sd/-

SANJAY DOSHI
Proprietor
C.P. No.: 7595

AUDITORS' REPORT

TO THE MEMBERS OF ANUH PHARMA LIMITED

1. We have audited the attached Balance Sheet of ANUH PHARMA LIMITED ("Company") as at March 31, 2010 and the related Profit and Loss Account and the Cash Flow Statement of the Company for the year ended on that date annexed thereto. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.
2. We conducted our audit in accordance with auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
3. As required by the Companies (Auditor's Report) Order, 2003 issued by the Central Government of India in terms of sub-section (4A) of Section 227 of the Companies Act, 1956 and as amended by the Companies (Auditor's Report) (Amendment) Order, 2004, we enclose in the Annexure a statement on the matters specified in paragraphs 4 and 5 of the said Order.
4. Further to our comments in the Annexure referred to in paragraph 3 above, we report that:
 - (a) We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law, have been kept by the Company so far as appears from our examination of those books;
 - (c) The Balance Sheet, Profit and Loss Account and Cash Flow Statement dealt with by this report are in agreement with the books of account;
 - (d) In our opinion, the Balance Sheet, Profit & Loss Account and Cash Flow Statement dealt with by this report comply with the Accounting Standards referred to in sub-section (3C) of Section 211 of the Companies Act, 1956.
 - (e) On the basis of written representations received from the directors as on March 31, 2010 and taken on record by the Board of Directors, we report that none of the director is disqualified as on March 31, 2010 from being appointed as a director in terms of clause (g) of sub-section (1) of Section 274 of the Companies Act, 1956;
 - (f) In our opinion and to the best of our information and according to the explanations given to us, the said accounts give the information required by the Companies Act, 1956, in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:
 - (i) in the case of the Balance Sheet, of the state of affairs of the Company as at March 31, 2010; and
 - (ii) in the case of the Profit and Loss Account, of the profit of the Company for the year ended on that date; and
 - (iii) in the case of the Cash Flow Statement, of the cash flows of the Company for the year ended on that date.

For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W

SAMIR S. MOGUL
Partner

Membership No. 100731

Place : Mumbai
Date : August 6, 2010

ANNEXURE TO THE AUDITORS' REPORT

As referred to in paragraph 3 of our report of even date on the accounts for the year ended March 31, 2010,

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- (b) As explained to us, physical verification of a major portion of fixed assets was conducted by the management during the year. In our opinion, the frequency of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such physical verification.
- (c) The fixed assets disposed off during the year are not substantial and hence, it has not affected the going concern assumption.
- (ii) (a) The inventory has been physically verified during the year by the management. In our opinion, the frequency of verification is reasonable.
- (b) The procedures of physical verification of inventories followed by the management are reasonable and adequate in relation to the size of the Company and the nature of its business.
- (c) The Company is maintaining proper records of inventory. The discrepancies noticed on verification between the physical stocks and the book records were not material.
- (iii) (a) The Company has not granted or taken loan, secured or unsecured, to or from any party covered in the register maintained under Section 301 of the Companies Act, 1956 and hence, the provisions of clause 4(iii)(b) to 4(iii)(g) of the Companies (Auditor's Report) Order, 2003 are not applicable to the Company.
- (iv) In our opinion and according to the information and explanations given to us, there are adequate internal control procedures commensurate with the size of the Company and the nature of its business with regard to the purchases of inventory and fixed assets and with regard to the sale of goods and services. During the course of our audit, we have not observed any continuing failure to correct major weaknesses in internal control.
- (v) (a) According to the information and explanations given to us, we are of the opinion that the particulars of the contracts and arrangements referred to in Section 301 of the Companies Act, 1956 have been so entered.
- (b) In our opinion and according to the information and explanations given to us, the transactions made in pursuance of such contracts and arrangements entered in the register maintained under Section 301 of the Companies Act, 1956 and exceeding the value of Rs. 500,000 in respect of each party during the year have been made at prices which are reasonable having regard to prevailing market prices at the relevant time where such market prices are available.
- (vi) The Company has not accepted any deposit from the public to which the provisions of Section 58A and Section 58AA or any other relevant provisions of the Companies Act, 1956 and the Companies (Acceptance of Deposits) Rules, 1975 apply.
- (vii) The Company has an internal audit system commensurate with its size and nature of its business.
- (viii) According to the information and explanations given to us, the Central Government has not prescribed the maintenance of cost records under Section 209(1)(d) of the Companies Act, 1956 for the Company.
- (ix) (a) According to the information and explanations given to us, the Company is generally regular in depositing with appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income tax, wealth tax, service tax, custom duty, cess and other material statutory dues applicable to it. According to the information and explanations given to us, the following undisputed amounts payable in respect of above were in arrears as at March 31, 2010 for a period of more than six months from the date on which they became payable:

Statement of Undisputed Dues				
Sr. No.	Name of the Statute	Nature of the Dues	Amount (Rs.)	Financial Year to which the amount relates
1.	Income-tax Act, 1961	Income-tax deducted at source ("TDS") on Rent	34,000	2009-2010
2.	Income-tax Act, 1961	TDS on Contractors	3,800	2009-2010
3.	Income-tax Act, 1961	TDS on Professional Fees	80	2009-2010
4.	The Maharashtra State Tax on Professions, Trades, Callings and Employments Act, 1975	Profession Tax	2,500	2009-2010
Total			40,380	

- (b) According to the information and explanations given to us, the dues as on March 31, 2010 in respect of income tax, sales tax, wealth tax, service tax, customs duty, excise duty, cess that have not been deposited with the appropriate authorities on account of any dispute are as under:

Statement of Disputed Dues					
Sr. No.	Name of the Statute	Nature of the Dues	Amount (Rs.)	Financial Year to which the amount relates	Forum where dispute is pending
1.	Bombay Sales Tax Act, 1959	Sales Tax Interest Penalty	627,925 635,859 2,000	1991-1992	The figures in the amount column are as per the orders dated April 10, 2003 of the Assistant Commissioner of Sales Tax (Appeals), Thane. Thereafter, the Company had preferred an appeal before the Maharashtra Sales Tax Tribunal, which has passed its orders on August 27, 2009. However, the Company has not yet received the revised assessment orders giving effect to the above referred Tribunal orders. The Company now plans to file a Writ Petition before the Honourable High Court of Bombay contesting the Tribunal order.
2.	Central Sales Tax Act, 1956	Sales Tax Interest	645,790 2,500	1991-1992	
3.	Bombay Sales Tax Act, 1959	Sales Tax Interest Penalty	150,645 246,007 500	1992-1993	
4.	Central Sales Tax Act, 1956	Sales Tax Interest Penalty	148,262 241,880 2,000	1992-1993	
Total			2,703,368		

- (x) The Company does not have accumulated losses at the end of the financial year and has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- (xi) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of dues to banks. The Company has not taken any loans from a financial institution nor issued any debentures.
- (xii) In our opinion and according to the information and explanations given to us, the Company has not granted any loans and advances on the basis of security by way of pledge of shares, debentures and other securities.
- (xiii) In our opinion, the Company is not a chit fund or a nidhi / mutual benefit fund / society. Therefore, the provisions of clause 4(xiii) of the Companies (Auditor's Report) Order, 2003 are not applicable to the Company.
- (xiv) In our opinion, the Company is not dealing or trading in shares, securities, debentures and other investments. Therefore, the provisions of clause 4(xiv) of the Companies (Auditor's Report) Order, 2003 are not applicable to the Company.
- (xv) According to the information and explanations given to us, the Company has not given any guarantee for loans taken by others from banks or financial institutions.

- (xvi) In our opinion and according to the information and explanations given to us, the Company has not taken any term loans. Accordingly, the provisions of clause 4(xvi) of the Companies (Auditor's Report) Order, 2003 are not applicable to the Company.
- (xvii) In our opinion and according to the information and explanations given to us and on an overall examination of the Balance Sheet of the Company, we report that no funds raised on short-term basis have been used for long-term investment.
- (xviii) During the year, the Company has not made any preferential allotment of shares to parties and companies covered in the register maintained under Section 301 of the Companies Act, 1956.
- (xix) During the year, the Company has not issued any secured debentures. Therefore, the provisions of clause 4(xix) of the Companies (Auditor's Report) Order, 2003 are not applicable to the Company.
- (xx) During the year, the Company has not raised any money by public issues.
- (xxi) According to the information and explanations given to us, no fraud on or by the Company has been noticed or reported during the course of our audit.

Place : Mumbai
Date : August 6, 2010

For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W
SAMIR S. MOGUL
Partner
Membership No. 100731

AUDITOR'S CERTIFICATE

The Board of Directors
ANUH PHARMA LTD.
A-3 Shiv Sagar Estate, North Wing,
Dr. Annie Besant Road,
Worli,
Mumbai - 400 018

Dear Sirs,


We have examined the Cash Flow Statement for the year ended on March 31, 2010. The Statement has been prepared by the Company in accordance with the requirement of clause 32 of the Listing Agreement with Bombay Stock Exchange Limited and is based on and in agreement with the corresponding Balance Sheet and Profit & Loss Account of the Company for the year ended on March 31, 2010 covered by our report of even date to the members of the Company.

For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W
SAMIR S. MOGUL
Partner
Membership No. 100731

Place : Mumbai
Date : August 6, 2010

PERFORMANCE OF THE COMPANY FOR THE LAST 10 YEARS

Rupees in Lakhs



FINANCIAL SUMMARY

Rupees in Lakhs

	2000-01	2001-02	2002-03	2003-04	2004-05	2005-06	2006-07	2007-08	2008-09	2009-10
CAPITAL ACCOUNT										
Share Capital	69.6	69.6	69.6	69.6	69.6	69.6	139.2	139.2	139.2	139.2
Reserves	957	1282	1569	2058	2368	2842	3237	3755	4282	5241
Borrowings	33	52	2	127	20	147	147	221	43	301
Gross Block	202	194	293	312	554	1033	1112	1295	1465	1559
Net Block	82	64	172	159	367	810	766	858	917	902
REVENUE ACCOUNT										
Profit before Depreciation & Tax	345	515	541	865	751	1054	1173	1249	1438	1870
Profit before Tax	329	495	523	830	718	1013	1050	1142	1325	1754
Profit After Tax	258	398	385	607	469	664	689	778	872	1255
Sales & Other Income	3042	3351	3718	5547	5392	7981	8390	11410	12227	17323
Earnings per Share (Rs.)	37.02	57.18	55.26	86.63	66.98	95.43	24.74	27.96	31.31	45.07
Dividend per Share (Rs.)	6.00	10.00	12.50	15.00	20.00	24.00	7.00	8.00	11.50	10.00

Note : The face value of the Company's equity share has been reduced from Rs. 10 to Rs. 5 effective from August 7, 2006.

BALANCE SHEET AS AT 31ST MARCH, 2010

	Schedule	As At 31.03.2010 Rupees	As At 31.03.2009 Rupees
SOURCES OF FUNDS			
Shareholders' Funds			
Share Capital	1	13,920,000	13,920,000
Reserves and Surplus	2	524,138,706	428,212,116
		538,058,706	442,132,116
Loan Funds			
Secured Loans	3	30,061,194	4,276,505
		30,061,194	4,276,505
Deferred Tax Liability (Net)	4	682,941	796,218
	TOTAL	568,802,841	447,204,839
APPLICATION OF FUNDS			
Fixed Assets			
Gross Block (At Cost)	5	136,361,878	128,877,731
Less: Depreciation to date		(65,668,774)	(54,799,650)
Net Block		70,693,104	74,078,081
Capital Work-in-Progress		19,541,408	17,649,733
		90,234,512	91,727,814
Investments	6	257,249,232	241,191,747
Deferred Tax Asset (Net)	4	-	-
Current Assets, Loans and Advances			
Inventories	7	105,234,068	64,867,905
Sundry Debtors	8	334,741,950	203,064,849
Cash and Bank Balances	9	113,652,200	76,774,768
Loans and Advances	10	199,859,724	159,300,148
		753,487,942	504,007,670
Less: Current Liabilities and Provisions			
Current Liabilities	11	374,593,800	209,331,095
Provisions	12	157,575,045	180,391,297
		532,168,845	389,722,392
Net Current Assets		221,319,097	114,285,278
	TOTAL	568,802,841	447,204,839
SIGNIFICANT ACCOUNTING POLICIES	19		
NOTES ON ACCOUNTS	20		

The Schedules referred to above form an integral part of the Balance Sheet.

As per our report of even date

For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W

For **ANUH PHARMA LIMITED**

SAMIR S. MOGUL
Partner
Membership No. 100731
Mumbai : August 6, 2010

L. P. SHAH
Director
BIPIN SHAH
Director

Mumbai : August 6, 2010

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH, 2010

	Schedule	Year ended 31.03.2010 Rupees	Year ended 31.03.2009 Rupees
INCOME			
Gross Sales and Operating Income	13	1,746,801,062	1,297,823,115
Less: Excise Duty		(101,079,179)	(92,688,416)
Net Sales and Operating Income		1,645,721,883	1,205,134,699
Other Income	14	86,619,964	17,529,244
	TOTAL	1,732,341,846	1,222,663,943
EXPENDITURE			
Cost of Traded Goods	15	24,595,504	116,092,669
Manufacturing Cost	16	1,454,255,783	900,254,444
Selling and Administrative Expenses	17	65,273,347	53,871,236
Interest paid	18	1,113,755	8,327,899
Depreciation	5	11,582,044	11,224,089
	TOTAL	1,556,820,433	1,089,770,337
PROFIT			
Profit before Prior Period Items		175,521,414	132,893,607
Less : Prior Period Items		(168,899)	(345,135)
Profit before Tax		175,352,515	132,548,472
Less: Provision for Taxation			
Current Income Tax	(50,000,000)		(44,000,000)
Wealth Tax	(50)		(14,000)
Fringe Benefit Tax	-		(450,000)
Deferred Tax	113,277		(921,584)
		(49,886,773)	(45,385,584)
Profit after Tax		125,465,741	87,162,888
Add/(Less) : Balance brought forward from previous year		41,793,836	34,233,991
Income-tax adjustments of earlier years		3,032,256	2,854,077
PROFIT AVAILABLE FOR APPROPRIATION:		170,291,833	124,250,956
APPROPRIATIONS			
Interim Dividend		27,840,000	-
Tax on Interim Dividend		4,731,408	-
Proposed Final Dividend		-	32,016,000
Tax on Proposed Final Dividend		-	5,441,120
Transfer to General Reserve		50,000,000	45,000,000
Credit Balance carried to the Balance Sheet		87,720,425	41,793,836
		170,291,833	124,250,956
SIGNIFICANT ACCOUNTING POLICIES	19		
NOTES ON ACCOUNTS	20		
EARNINGS PER SHARE	20		
Face Value of Rs. 5 per Equity Share			
Basic & Diluted		45.07	31.31

The Schedules referred to above form an integral part of the Profit & Loss Account.

As per our report of even date

For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W

For **ANUH PHARMA LIMITED**

SAMIR S. MOGUL
Partner
Membership No. 100731
Mumbai : August 6, 2010

L. P. SHAH **BIPIN SHAH**
Director *Director*

Mumbai : August 6, 2010

SCHEDULES FORMING PART OF ACCOUNTS

	Rupees	As At 31.03.2010 Rupees	As At 31.03.2009 Rupees
SCHEDULE - 1			
SHARE CAPITAL			
Authorised			
20,000,000 Equity Shares of Rs. 5 each (Previous year 3,000,000 Equity Shares of Rs.5 each)		100,000,000	15,000,000
Issued			
2,784,000 Equity Shares of Rs. 5 each		13,920,000	13,920,000
Paid-up			
2,784,000 Equity Shares of Rs. 5 each fully paid-up (Out of which 4,000 Equity Shares of Rs.5 each were issued as fully paid-up for consideration other than cash pursuant to a contract and 2,610,000 Equity Shares of Rs. 5 each were issued as fully paid-up Bonus Shares by utilisation from General Reserve)		13,920,000	13,920,000
TOTAL		13,920,000	13,920,000
Notes:			
(a) The shareholders of the Company had approved the sub-division of Equity Shares of the Company having nominal / face value of Rs.10 each into Equity Shares having nominal / face value of Rs. 5 each at the Extraordinary General Meeting ('EGM') held on June 9, 2006.			
(b) Consequently, the Authorised, Issued and Paid-up Share Capital were divided from Rs.10 per Equity Share to Rs. 5 per Equity Share.			
(c) Simultaneously, the shareholders of the Company at the above referred EGM had also approved the allotment of 1,392,000 bonus Equity Shares of Rs. 5 each in the ratio of 1:1 to the existing shareholders by capitalisation of reserves.			
SCHEDULE - 2			
RESERVES AND SURPLUS			
General Reserve			
As per last Balance Sheet	385,668,280		340,540,000
Add: Initial adoption of Accounting Standard 15 'Employee Benefits'	-		128,280
Add: Transferred from Profit and Loss Account	50,000,000		45,000,000
		435,668,280	385,668,280
Special Capital Incentive Reserve			
As per last Balance Sheet		750,000	750,000
Profit & Loss Account:			
		87,720,425	41,793,836
TOTAL		524,138,705	428,212,116
SCHEDULE - 3			
SECURED LOANS			
From Bank of India			
Cash Credit (in Rupees)		30,061,194	-
Packing Credit (in Rupees) (Secured against hypothecation of stock in trade lying at factory, book debts and first charge-cum-equitable mortgage on factory land and building at Tarapur, Boisar, and personal guarantee of some of the directors of the Company)		-	1,564,323
Loan against Fixed Deposits (Secured against Fixed Deposits)		-	2,712,182
TOTAL		30,061,194	4,276,505

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

	As At 31.03.2010 Rupees	As At 31.03.2009 Rupees
SCHEDULE - 4		
DEFERRED TAX LIABILITY / (ASSET) (Net):		
Deferred Tax Liability		
Depreciation on Fixed Assets	469,294	1,564,399
	"A"	469,294
Deferred Tax Asset		
Expenses allowable only on payment basis	1,152,236	768,181
	"B"	1,152,236
TOTAL ("A" - "B")	(682,942)	796,218

**SCHEDULE - 5
FIXED ASSETS**

Sr. Description No.	GROSS BLOCK				DEPRECIATION			NET BLOCK		
	Cost as at 1-4-2009	Additions during the year	Deductions during the year	Cost as at 31-3-2010	Balance as at 1-4-2009	Provided for the year	Deductions during the year	Balance as at 31-3-2010	Balance as at 31-3-2010	Balance as at 31-3-2009
I TANGIBLE ASSETS										
1 Building:										
Office Premises (see Note a below)	14,760,354	–	–	14,760,354	2,971,969	589,419	–	3,561,388	11,198,966	11,788,385
Factory Building	34,984,624	3,653,925	–	38,638,549	11,531,873	2,548,493	–	14,080,366	24,558,183	23,452,751
	49,744,978	3,653,925	–	53,398,903	14,503,842	3,137,912	–	17,641,754	35,757,149	35,241,136
2 Leaseholds:										
Leasehold Land	3,563,940	–	–	3,563,940	161,824	46,257	–	208,081	3,355,859	3,402,116
3 Plant & Machinery:										
Plant and Machinery	33,756,010	910,941	–	34,666,951	18,512,522	4,387,932	–	22,900,454	11,766,497	15,243,488
Laboratory Equipments	5,456,369	335,000	–	5,791,369	2,225,630	476,972	–	2,702,602	3,088,766	3,230,738
Material Storage & Handling Equipments	5,580,414	136,000	61,222	5,655,192	3,870,336	456,247	39,673	4,286,910	1,368,282	1,710,078
Plumbing Installations	258,422	–	–	258,422	256,841	220	–	257,061	1,361	1,581
Electric Installations	7,195,473	520,538	–	7,716,011	3,290,322	583,477	–	3,873,799	3,842,212	3,905,151
Airconditioning Equipments & Refrigerators	10,038,510	368,086	–	10,406,596	4,327,430	822,539	–	5,149,969	5,256,627	5,711,080
Computer Hardware	2,210,408	265,443	–	2,475,851	1,798,613	243,943	–	2,042,556	433,295	411,795
Office Equipments	1,649,425	64,660	–	1,714,085	812,163	121,236	–	933,399	780,686	837,262
	66,145,031	2,600,668	61,222	68,684,477	35,093,857	7,092,566	39,673	42,146,750	26,537,727	31,051,174
4 Furniture and Fixtures:										
Furniture and Fixtures	4,372,295	645,660	–	5,017,955	2,641,076	377,049	–	3,018,125	1,999,830	1,731,219
5 Vehicals:										
Motor Vehicles (see Note b below)	4,961,487	1,056,121	864,492	5,153,116	2,343,792	778,175	673,246	2,448,721	2,704,395	2,617,695
II INTANGIBLE ASSETS:										
1 Computer Software	90,000	453,487	–	543,487	55,259	150,083	–	205,342	338,145	34,741
	128,877,731	8,409,861	925,714	136,361,878	54,799,650	11,582,042	712,919	65,668,774	70,693,104	74,078,081
Capital Work-in-Progress	17,649,733	1,891,675	–	19,541,408	–	–	–	–	19,541,408	17,649,733
TOTAL	146,527,464	10,301,536	925,714	155,903,286	54,799,650	11,582,042	712,919	65,668,774	90,234,512	91,727,814
Previous Year	129,525,964	17,271,749	270,249	146,527,464	43,771,661	11,224,089	196,099	54,799,650	91,727,814	85,754,302

Notes:

- a Office Premises includes value of shares of a co-operative society.
b Some of the Motor Vehicles are held in the name of one of the Directors of the Company.

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

	As At 31.03.2010 Rupees	As At 31.03.2009 Rupees
SCHEDULE - 6		
INVESTMENTS (NON-TRADE; AT COST; UNQUOTED):		
In Units of Mutual Funds:		
Long-Term		
Nil (Previous year 1,000,000.00) units of Birla Sun Life FTP - INSTL - Series AN - Growth of Birla Sun Life Mutual Fund	-	10,000,000
Nil (Previous year 1,000,000.00) units of HDFC FMP 370 Days July 2008 (VIII) (1) Wholesale Plan Growth of HDFC Mutual Fund	-	10,000,000
Nil (Previous year 7,301,562.603) units of HDFC MIP Long Term Growth of HDFC Mutual Fund	-	122,500,000
11,724,699.752 (Previous year Nil) units of HDFC MIP Long Term Quarterly Dividend Payout of HDFC Mutual Fund	150,000,000	-
496,007.143 (Previous year Nil) units of ICICI Prudential Long Term Plan Premium Cumulative of ICICI Prudential Mutual Fund	5,000,000	-
4,000,000.00 (Previous year Nil) units of Tata FMP Series 25 Scheme A Super High Invest Plan - Growth of Tata Mutual Fund	40,000,000	-
Nil (Previous year 2,735,926.947) units of UTI MIS Advantage Plan - Growth Option of UTI Mutual Fund	-	44,000,000
"A"	195,000,000	186,500,000
Current:		
6,213,029.569 (Previous year 5,210,837.379) units of HDFC Cash Management Fund - Treasury Advantage (erstwhile Savings Plus) - Wholesale Plan - Weekly Dividend Payout	62,249,232	52,191,747
"B"	62,249,232	52,191,747
TOTAL ("A" + "B")	257,249,232	238,691,747
In Government Securities:		
Long-Term:		
Nil (Previous year 25,000) units of 6.60% Tax Free ARS Bonds of Unit Trust of India (Face Value Rs.100 each; maturing on 1-4-2009)	-	2,500,000
"C"	-	2,500,000
TOTAL ("A" + "B" + "C")	257,249,232	241,191,747

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

	As At 31.03.2010	As At 31.03.2009
Rupees	Rupees	Rupees
SCHEDULE - 7		
INVENTORIES		
(As taken, valued and certified by the Managing Director)		
Raw Materials	47,556,246	29,576,803
Work-In-Progress	5,568,177	5,113,769
Finished Goods (Manufacturing)	51,542,727	29,765,068
Finished Goods (Traded)	-	-
	51,542,727	29,765,068
Light Diesel Oil	227,094	229,410
Packing Materials	339,824	182,855
TOTAL	105,234,068	64,867,905
SCHEDULE - 8		
SUNDRY DEBTORS		
(Unsecured, considered good)		
Sundry Debtors		
Outstanding for a period exceeding six months	4,568,360	-
Others	330,173,590	203,064,849
Note:		
Sundry Debtors includes amounts due from Companies / Firms in which some of the directors are interested as directors / partners; refer note 10 of Schedule 20		
TOTAL	334,741,950	203,064,849
SCHEDULE - 9		
CASH AND BANK BALANCES		
Cash on Hand	105,042	160,600
Balances with Scheduled Banks:		
In Cash Credit Accounts	5,504	5,504
In Current Accounts	26,680,557	135,392
In Fixed Deposits (Margin Money; under lien)	85,186,000	75,211,000
In Unclaimed Dividend Accounts	1,675,097	1,262,272
	113,547,158	76,614,168
TOTAL	113,652,200	76,774,768

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

	Rupees	Year ended 31.03.2010 Rupees	Year ended 31.03.2009 Rupees
SCHEDULE - 13			
GROSS SALES AND OPERATING INCOME			
Gross Sales:			
Manufacturing:			
Export	620,775,420		462,550,520
Domestic	1,046,764,676		643,659,798
Add: Procurement and Service Charges (TDS Rs. 668,971; Previous year Rs. Nil)	49,671,338		36,707,107
	<u>1,096,436,014</u>		<u>680,366,905</u>
		1,717,211,434	1,142,917,425
Trading:			
Export	10,612,598		101,562,226
Domestic	17,941,750		52,301,840
		<u>28,554,348</u>	<u>153,864,066</u>
		1,745,765,782	1,296,781,491
Processing & Micronising Charges (Gross) (TDS Rs. 22,440; Previous year Rs. 148,532)		1,035,280	1,041,624
TOTAL		<u><u>1,746,801,062</u></u>	<u><u>1,297,823,115</u></u>
SCHEDULE - 14			
OTHER INCOME			
Interest received (Gross):			
on Loan (TDS Rs. 63,560; Previous year Rs. 54,410)		280,480	240,067
from Bank (TDS Rs. 770,200; Previous year Rs. 943,980)		7,703,179	4,583,394
on Investments (tax-free)		-	165,000
from Others (TDS Rs. 1,612; Previous year Rs. 11,657)		255,647	67,193
		<u>8,239,306</u>	<u>5,055,654</u>
Profit on Sale of Investments		28,570,428	6,534,998
Dividend on Investments (tax-free)		7,337,608	2,711,597
Export Incentives		17,695,541	2,569,101
Profit on Sale of Fixed Assets		135,127	163,350
Miscellaneous Income (Gross) [TDS Rs.Nil; Previous year Rs.10,425]		171,980	494,544
Foreign Exchange Gain		21,338,969	-
Technology Transfer Fee		811,194	-
Sundry balance written back		2,293,211	-
Insurance Claim received		26,600	-
TOTAL		<u><u>86,619,964</u></u>	<u><u>17,529,244</u></u>
SCHEDULE - 15			
COST OF TRADED GOODS			
Opening Stock		-	9,197,047
Add: Purchases	4,960,973		76,065,943
Add: Transferred from Raw Materials	19,634,531		30,829,679
		<u>24,595,504</u>	<u>106,895,622</u>
		<u>24,595,504</u>	<u>116,092,669</u>
Less : Closing Stock		-	-
TOTAL		<u><u>24,595,504</u></u>	<u><u>116,092,669</u></u>

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

	Rupees	Year ended 31.03.2010 Rupees	Year ended 31.03.2009 Rupees
SCHEDULE - 16			
MANUFACTURING COST			
Opening Stock of Semi-Finished and Finished Goods		34,878,837	21,073,160
Raw Materials Consumed :			
Opening Stock	29,576,803		44,931,226
Add : Purchases	<u>1,455,963,328</u>		<u>827,854,526</u>
	1,485,540,131		872,785,752
Less : Transferred to Cost of Traded Goods	19,634,531		30,829,679
Less : Closing Stock	<u>47,556,246</u>		<u>29,576,803</u>
		1,418,349,354	812,379,270
Packing Material Consumed		8,054,519	3,788,845
Personnel Expenses :			
Salary and Allowances	9,914,966		8,533,387
Contribution to Provident & Other Funds	315,539		262,468
Bonus	<u>544,107</u>		<u>509,653</u>
		10,774,612	9,305,508
Processing & Micronising Charges		15,045,778	13,539,198
Consumable Stores		311,573	260,306
Power and Fuel:			
Oil, Fuel, Ice, Water Charges and Gas Consumed	4,231,975		3,439,730
Electricity Charges	<u>9,875,285</u>		<u>7,146,049</u>
		14,107,260	10,585,779
Foreign Exchange Loss		-	54,311,966
Testing Charges		449,629	339,446
Laboratory Expenses :			
Laboratory Glassware	504,173		422,664
Laboratory Chemicals	<u>792,004</u>		<u>860,770</u>
		1,296,177	1,283,434
Effluent Treatment Charges		217,569	113,497
Repairs and Maintenance to :			
Machineries	3,722,213		3,309,719
Building	2,539,654		1,284,118
Electrical	394,706		628,027
Plumbing	335,651		2,454,468
Others	<u>889,155</u>		<u>476,540</u>
		7,881,379	8,152,872
		1,511,366,687	935,133,281
Less: Closing Stock of Semi-Finished and Finished Goods		57,110,904	34,878,837
TOTAL		1,454,255,783	900,254,444

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

	Year ended 31.03.2010	Year ended 31.03.2009
	Rupees	Rupees
SCHEDULE - 17		
SELLING AND ADMINISTRATIVE EXPENSES		
Managerial Remuneration:		
Remuneration to Managing Director	2,965,417	2,406,390
Directors' Meeting Fees	157,500	189,000
	3,122,917	2,595,390
Payment to and Provision for Employees:		
Salaries & Allowances	6,641,743	6,217,834
Contribution to Provident & Other Funds	250,181	235,319
Bonus	259,580	231,388
Group Gratuity Premium	144,023	170,438
Staff Welfare Expenses	1,299,663	1,345,478
	8,595,190	8,200,457
Travelling & Conveyance Expenses	3,457,103	3,526,818
Shipment and Export Expenses:		
Manufactured Goods	12,380,377	8,166,448
Traded Goods	52,587	531,370
	12,432,964	8,697,818
Freight and Forwarding	1,499,143	1,235,748
Insurance Charges	1,391,576	1,240,043
Rent	23,001	202,731
Rates and Taxes:		
Sales Tax	217,075	40
Profession Tax	-	2,500
Banking Cash Transaction Tax	-	5,952
Service Tax	181,144	604,370
	398,219	612,862
Motor Vehicle Expenses	1,645,476	1,744,420
Repairs and Maintenance to Other Assets	203,824	234,572
Bank Charges	7,474,505	6,846,199
Postage, Telegram and Telephone Expenses	1,145,202	1,088,526
Brokerage and Commission	10,395,400	7,963,653
Membership Fees and Subscription	57,915	46,328
Sales Promotion Expenses	2,821,371	904,561
Legal and Professional Charges	1,961,281	2,245,826
Power & Fuel Charges	675,240	-
Statutory Auditor's Remuneration:		
As Auditor	248,175	251,547
As Adviser:		
Taxation Matters	63,974	92,744
Financial Matters	11,030	11,236
In Other Capacity:		
Tax Audit	55,150	55,150
Certification	-	-
	378,329	410,677
Provision for Loss on Current Investments	-	31,019
Donation	901,751	30,000
Miscellaneous Expenses	6,692,941	6,013,588
TOTAL	65,273,347	53,871,236

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

	Year ended 31.03.2010 Rupees	Year ended 31.03.2009 Rupees
SCHEDULE - 18		
INTEREST PAID:		
To Bank	307,097	7,284,834
To Managing Director	-	602,307
To Others	806,658	440,758
TOTAL	1,113,755	8,327,899

SCHEDULE - 19

STATEMENT ON SIGNIFICANT ACCOUNTING POLICIES:

1. Method of Accounting:

The Financial Statements are prepared under the historical cost convention in accordance with the applicable Accounting Standards and the relevant provisions of the Companies Act, 1956. Further, the Company follows the mercantile system of accounting and recognises income and expenditure on accrual basis except in the case of significant uncertainties.

2. Inflation:

Assets and Liabilities are recorded at historical cost to the Company. These costs are not adjusted to reflect the changing value of the purchasing power of money.

3. Fixed Assets:

Fixed assets are stated at cost of acquisition which includes taxes, duties and other identifiable direct expenses net of modvat credit availed less accumulated depreciation.

4. Depreciation:

Depreciation is provided on a pro-rata basis at the written down value method as per the rates prescribed in Schedule XIV of the Companies Act, 1956. However, in the case of Leasehold Land, depreciation has been provided on pro-rata basis using the straight line method over the period of the lease.

5. Investments:

Long Term investments are stated at the cost of acquisition, except where there is diminution in value other than temporary in which case the carrying value is reduced to recognize the decline. Current Investments are stated at the cost of acquisition or fair value, whichever is lower.

6. Inventories:

Raw Materials and Packing Materials are stated at cost net of modvat credit and sales tax setoff. Work in process and Finished Goods include indirect production overheads. Finished goods lying in the factory are valued inclusive of excise duty payable thereon. Finished goods are valued at lower of cost or net realisable value.

7. Foreign Currency Transactions:

Transactions in foreign currency are recorded at the exchange rate prevailing at the date of the transaction. Assets and liabilities denominated in foreign currency are translated into rupees at the exchange rate prevailing on the date of the Balance Sheet. Gain or loss in the exchange rate is accounted on payment or realisation basis.

8. Sales:

Sale of products is recognized at the point of dispatch to the customer. Gross Sales are inclusive of excise duty and exclusive of taxes.

9. Retirement Benefits:

Contribution to provident fund is charged to the Profit & Loss Account as incurred. The liability for payment of gratuity is covered through the Group Gratuity Scheme. Gratuity and Leave encashment benefits are accounted for based on actuarial valuations.

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

10. Taxation:

Provision for income tax is made for both current and deferred taxes. Provision for current income tax is made on the current tax rates based on the assessable income. The Company provides for deferred tax based on the tax effect of timing differences resulting from the recognition of items in the financial statements and in estimating its current tax provision. Deferred tax assets are recognized where there is certainty that there will be sufficient future taxable income available against which such deferred tax assets can be realized.

Provision for wealth tax is made based on the taxable assets.

Provision for fringe benefit tax is made based on the fringe benefits provided during the year.

11. Impairment of Assets:

At each Balance Sheet date, the Company reviews the carrying amounts of its assets to determine whether there is any indication that those assets suffered any impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of impairment loss. Recoverable amount is the higher of an asset's net selling price and value in use. In assessing the value in use, the estimated future cash flows expected from the continuing use of the asset and from its disposal are discounted to its present value using a discount rate that reflects the current market assessment of the time value of money and the risks specific to the asset. An impairment loss is recognised whenever the carrying amount of an asset exceeds its recoverable amount. Reversal of impairment loss is recognised immediately as income in the Profit & Loss Account.

12. Sundry Debtors and Loans and Advances:

Sundry debtors and loans and advances are stated after making adequate provisions for doubtful balances.

13. Borrowing Costs:

Borrowing costs attributable to the acquisition / construction of qualifying assets are capitalized and form part of the cost of the qualifying assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue as an expense.

14. Provisions and Contingencies:

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to present value and are determined based on best estimate required to settle the obligation at Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. Contingent assets and liabilities are not recognised.

15. Material Events:

Material events occurring after the balance sheet date are taken into cognizance.

16. Other Accounting Policies:

These are consistent with the generally accepted accounting practices.

SCHEDULE - 20

NOTES ON ACCOUNTS:

1. (a) Managerial Remuneration:

	2009-2010 Rupees	2008-2009 Rupees
(i) Remuneration to Managing Director:		
Salary	1,304,000	960,000
Contribution to Provident Fund	132,480	115,200
Commission	1,497,699	1,284,765
Perquisites	31,238	46,425
	<u>2,965,417</u>	<u>2,406,390</u>
(ii) Meeting Fees to other Directors	157,500	189,000
TOTAL	<u><u>3,122,917</u></u>	<u><u>2,595,390</u></u>

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

	2009-2010 Rupees	2008-2009 Rupees
(b) Computation of Net Profit in accordance with Section 198 of the Companies Act, 1956 and calculation of commission payable to Managing Director:		
Profit before Taxation (as per Profit and Loss Account)	175,352,515	132,548,472
Add: Remuneration to Managing Director and Directors Meeting Fees	3,122,917	2,595,390
Depreciation provided in Accounts	11,582,044	11,224,089
Provision for Loss on Current Investments	-	31,019
Loss on Sale of Fixed Assets	-	-
	<u>190,057,476</u>	<u>146,398,970</u>
Less: Depreciation under Section 350 of the Companies Act, 1956	(11,582,044)	(11,224,089)
Profit on Sale of Fixed Assets	(135,127)	(163,350)
Profit on Sale of Investments	(28,570,428)	(6,534,998)
Net Profit as per Section 349 of the Companies Act, 1956	<u>149,769,877</u>	<u>128,476,532</u>
Commission at 1% of Net Profit as per Section 309 of the Companies Act, 1956	TOTAL 1,497,699	1,284,765

2. Particulars regarding Capacity, Production, Opening and Closing Stock and Turnover - as certified by the Managing Director (figures in bracket relate to previous year):

(a) Licensed Capacity : Not Applicable

(b) Installed Capacity (at year-end) and Actual Production:

Class of Product	Unit of Measure	Quantity	
		Installed Capacity	Actual Production
Antibiotics	Kg.	750,000 (600,000)	509,122 (394,670)

(c) Manufacturing Activity:

Class of Product	Unit of Measure	Opening Stock		Gross Turnover		Closing Stock	
		Qty.	Rupees	Qty.	Rupees	Qty.	Rupees
Antibiotics	Kg.	14,628 (10,180)	29,765,068 (15,805,711)	504,209 (390,222)	1,617,152,510 (1,050,285,659)	19,541 (14,628)	51,542,727 (29,765,068)
Excise Duty					100,058,924 (92,631,766)		
			<u>29,765,068</u> <u>(15,805,711)</u>		<u>1,717,211,434</u> <u>(1,142,917,425)</u>		<u>51,542,727</u> <u>(29,765,068)</u>

(d) Trading Activity:

Class of Product	Unit of Measure	Opening Stock		Purchase		Turnover		Closing Stock	
		Qty.	Rupees	Qty.	Rupees	Qty.	Rupees	Qty.	Rupees
Antibiotic	Kg.	-	-	6,301	18,861,112	6,301	21,669,640	-	-
		(5,016)	(8,958,807)	(49,809)	(105,220,243)	(54,825)	(151,944,112)	(-)	(-)
Other Chemicals*		-	-	-	5,734,392	-	6,884,708	-	-
		(-)	(238,240)	(-)	(1,675,379)	(-)	(1,919,954)	(-)	(-)
			-		24,595,504		28,554,348		-
			<u>(-)</u>		<u>(106,895,622)</u>		<u>(153,864,066)</u>		<u>(-)</u>

* Since the goods are purchased and sold in different units of measure, the quantity is not shown.

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

3. Raw Materials Consumed (figures in bracket relate to previous year):

Class of Product	Unit of Measure	Quantity	Rupees
Drug Intermediates & Chemicals	Kg.	1,455,934 (1,057,515)	1,418,349,354 (812,379,270)

4. Value of imported and indigenous raw materials consumed and percentage of each to total consumption:

	31-3-2010		31-3-2009	
	Rupees	%	Rupees	%
Indigenous	105,176,206	7	90,648,085	11
Imported	1,313,173,148	93	721,731,185	89
TOTAL	1,418,349,354	100	812,379,270	100

5. Earnings in Foreign Exchange:

	Current Year Rupees	Previous Year Rupees
F.O.B. Value of Exports	621,838,787	534,915,023
Technical Transfer Fees (included in other Income)	811,194	–
Miscellaneous Income	–	82,650
TOTAL	622,649,981	534,997,673

6. Expenditure in Foreign Currency:

	31-03-2010 Rupees	31-03-2009 Rupees
Purchase of Raw Materials and Traded Goods (CIF Value of Imports)	1,281,180,180	792,656,321
Travelling, Telephone & General Expenses	988,533	1,140,124
Commission	6,723,127	6,324,489
Exhibition Expenses (Gross)	1,438,620	1,373,726
Laboratory Equipment	–	791,679
TOTAL	1,290,330,460	802,286,339

7. The Company has not received the required information from Suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006. Hence disclosures, if any, relating to amounts unpaid as at the year end together with interest paid / payable as required under the said Act have not been made.

8. Segment Reporting:

In the opinion of the management, the Company's operations fall within a single segment, namely "Bulk drugs and Chemicals", and hence, there are no separate reportable segments as per Accounting Standard 17 "Segment Reporting".

9. Earning Per Share (EPS) as per Accounting Standard 20 "Earning Per Share":

The numerators and denominators used to calculate Basic and Diluted Earnings Per Share are as under:

		31-3-2010 Rupees	31-3-2009 Rupees
Profit attributable to the equity shareholders	(A)	125,465,741	87,162,888
Weighted average number of equity shares outstanding during the year (see Notes to Schedule 1)	(B)	2,784,000	2,784,000
Nominal value of equity shares (see Notes to Schedule 1)		5	5
Basic / diluted Earnings per share	(A)/(B)	45.07	31.31

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

10. (a) Related Party Disclosures as per Accounting Standard 18 "Related Party Disclosures" (figures in brackets relate to previous year):

Particulars	Entities under direct or indirect control or substantial influence		Key Management Personnel		Relatives of Key Management Personnel		Total	
(i) Transactions during the year:								
Sales								
a) S. Kant Pharma Pvt. Ltd.	–	(786,500)	–	(–)	–	(–)		
b) S. Kant Healthcare Ltd.	17,706,693	(57,846,072)	–	(–)	–	(–)		
c) S. K. Age Exports	4,065,000	(1,307,300)	–	(–)	–	(–)		
d) Eskay Speciality Chemicals	–	(11,200)	–	(–)	–	(–)		
e) S. K. Distributors	11,250	(–)	–	(–)	–	(–)		
TOTAL	21,782,943	(59,951,072)	–	(–)	–	(–)	21,771,693	(59,951,072)
Processing Charges Received								
a) S. Kant Healthcare Ltd.	478,800	(607,500)	–	(–)	–	(–)	478,800	(607,500)
Processing Charges Paid								
a) S. Kant Healthcare Ltd.	29,150	(118,625)	–	(–)	–	(–)	29,150	(118,625)
Purchases of Raw Material								
a) S. Kant Healthcare Ltd.	–	(575,955)	–	(–)	–	(–)	–	(575,955)
Reimbursement (receipt) of Exhibition Expenses								
a) S. Kant Pharma Pvt. Ltd.	180,972	(575,468)	–	(–)	–	(–)		
b) S. Kant Healthcare Ltd.	266,377	(575,468)	–	(–)	–	(–)		
TOTAL	447,349	(1,150,936)	–	(–)	–	(–)	447,349	(1,150,936)
Reimbursement (payment) of Exhibition Expenses								
a) S. Kant Pharma Pvt. Ltd.	50,000	–	–	(–)	–	(–)		
TOTAL	50,000	–	–	(–)	–	(–)	50,000	–
Interest received								
a) S. Kant Healthcare Ltd.	–	(190,849)	–	(–)	–	(–)	–	(190,849)
Interest paid								
a) Bipin N. Shah	–	(–)	–	(602,307)	–	(–)	–	(602,307)
Managing Director's Remuneration								
a) Bipin N. Shah	–	(–)	2,965,417	(2,406,396)	–	(–)	2,965,417	(2,406,396)
Director's Sitting Fees								
a) Bharat N. Shah	–	(–)	–	(–)	20,000	(13,500)	20,000	(13,500)
Service Charges Received								
a) S. K. Distributors	–	(411,894)	–	(–)	–	(–)	–	(411,894)
Sale of Asset								
a) S. K. Distributors	65,812	(–)	–	(–)	–	(–)	65,812	(–)
Loans taken during the year								
a) Bipin N. Shah	–	(–)	–	(20,360,000)	–	(–)	–	(20,360,000)
Loans repaid during the year								
b) Bipin N. Shah	–	(–)	–	(20,360,000)	–	(–)	–	(20,360,000)
Loans given during the year								
a) S. Kant Healthcare Ltd.	–	(7,500,000)	–	(–)	–	(–)	–	(7,500,000)
Loans given refunded during the year								
a) S. Kant Healthcare Ltd.	–	(7,500,000)	–	(–)	–	(–)	–	(7,500,000)
Stipend paid								
a) Vivek B. Shah	–	(–)	–	(–)	19,000	(57,000)	19,000	(57,000)
Salary Paid								
a) Vivek B. Shah	–	(–)	–	(–)	188,000	(–)		
b) Ritesh B. Shah	–	(–)	–	(–)	552,000	(480,000)		
c) G. C. Sharda	–	(–)	1,890,195	(1,614,455)	–	(–)		

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

Particulars	Entities under direct or indirect control or substantial influence		Key Management Personnel		Relatives of Key Management Personnel		Total	
d) Ketan N. Shah	-	(-)	-	(-)	238,814	(226,391)		
TOTAL	-	(-)	1,890,195	(1,614,455)	978,814	(706,391)	2,869,009	(2,320,846)
Sundry Balances written-off								
a) S. Kant Healthcare Ltd.	-	(1,555)	-	(-)	-	(-)		
b) S. Kant Pharma Pvt. Ltd.	-	(5,000)	-	(-)	-	(-)		
TOTAL	-	(6,555)	-	(-)	-	-	-	(6,555)
(ii) Year-end balances:								
Current Assets - Sundry Debtors								
a) S. Kant Healthcare Ltd.	1,534,937	(1,435,046)	-	(-)	-	(-)		
b) S. K. Age Exports	594,000	(585,000)	-	(-)	-	(-)		
TOTAL	2,128,937	(2,020,046)	-	(-)	-	(-)	2,128,937	(2,020,046)
Current Liabilities - Sundry Creditors								
a) Bipin N. Shah	-	(-)	1,495,149	(1,284,765)	-	(-)		
b) G. C. Sharda	-	(-)	1,770,195	(1,494,455)	-	(-)		
c) S. K. Distributors	-	(261,992)	-	(-)	-	(-)		
d) S. Kant Healthcare Ltd.	29,150	(575,955)	-	(-)	-	(-)		
TOTAL	29,150	(837,947)	3,265,344	(2,779,220)	-	(-)	3,294,494	(3,617,167)

Name of related parties and description of relationship (as certified by the management and relied upon by the auditor):

- Entities under direct or indirect control or substantial influence: S. Kant Pharma Pvt. Ltd (proprietor of Eskay Fine Chemicals), S Kant Healthcare Ltd, S.K. Age Exports, Bharti & Co., Sevantil Kantilal & Co., Sevantil Kantilal Pvt. Ltd., Sevak Pharma Pvt. Ltd., S.K. Age Exports, S.K. Pharma (Jogeshwari), S.K. Brothers, S.K. Distributors, Eskay Speciality Chemicals and Sevantil Kantilal Trust.
- Key Management Personnel: Bipin N. Shah (Managing Director) and G.C. Sharda (Chief Executive Officer)
- Relatives of Key Management Personnel: Bharat N. Shah, Bipin N. Shah (HUF), Ritesh B. Shah, Ketan N. Shah and Vivek B. Shah

(b) Additional disclosure as required by the amended clause 32 of the listing agreements with relevant stock exchanges (figures of the previous year have been given in brackets):

Name	Nature of Transaction	Balance as at year-end Rupees	Maximum amount Outstanding during the year Rupees	No. of shares of the company held by the loanees as at year-end Rupees
Loans and advances in the nature of loans to associates	- (-)	- (-)	- (-)	- (-)
Loans and Advances in the nature of loans to firms or companies in which directors are interested.				
S. Kant Healthcare Ltd.	Inter-corporate deposit	- (-)	- (7,500,000)	- (-)
Loans and advances in the nature of loans where there is:				
i) No repayment schedule		- (-)	- (-)	- (-)
ii) Repayment beyond 7 years		- (-)	- (-)	- (-)
iii) No Interest :	Loans to Employees	2,695,355 (920,297)	2,695,355 (1,095,750)	- (-)
iv) Interest below Section 372A of the Companies Act, 1956		- (-)	- (-)	- (-)

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

11. The following Investments were purchased and sold during the year:

Name of the Mutual Fund Scheme	Face Value of Unit Rupees	Quantity (units)	Purchase Cost Rupees	Sale Proceeds Rupees
HDFC Cash Management Fund				
- Treasury Advantage Plan	10	46,555,310.152	466,617,244.93	466,614,571.06
- Wholesale - Weekly Dividend				
ICICI Prudential Institutional Short Term Plan- Fortnightly Dividend Re-investment	10	7,053,392.755	85,433,359.07	84,905,746.65
Birla Sun Life Short Term Fund	10	1,102,933.206	11,035,398.19	11,035,398.19
- Retail - Daily Dividend Re-investment				

12. Contingent Liabilities:

Nature of the Dues	31-3-2010 Rupees	31-3-2009 Rupees
a. Guarantees issued by banks on behalf of the Company	1,219,015	4,167,207
b. Letters of Credit outstanding	208,262,661	298,400,000
c. Claims against the Company not acknowledged as debts:		
i Sales Tax (including interest and penalty)	2,703,368*	2,703,368
ii Income-tax	-	329,694
	2,703,368	3,033,062

* The figure of Rs.2,703,368 is as per the orders dated April 10, 2003 of the Assistant Commissioner of Sales Tax (Appeals), Thane. Thereafter, the Company had preferred an appeal before the Maharashtra Sales Tax Tribunal, which has passed its orders on August 27, 2009. However, the Company has not yet received the revised assessment orders giving effect to the above referred Tribunal orders. The Company now plans to file a Writ Petition before the Honourable High Court of Bombay contesting the Tribunal order.

13. The Company has imported certain raw materials and chemicals under the Advance License scheme without payment of duty subject to fulfilment of specified export obligations. However, the Company has yet to fulfil certain portion of these export obligations within the stipulated validity period. On a forward basis, the Company's management is confident of fulfilling these export obligations and hence, no provision for the duty payable, in case the export obligation is not fulfilled, has been made in the accounts.
14. (a) Details of the outstanding foreign exchanges derivative contracts entered into by the Company:

Derivative Contract	31-3-2010			31-3-2009		
	No. of Contracts	Foreign Currency	Rupees	No. of Contracts	Foreign Currency	Rupees
Forward Contract	-	-	-	4	US \$ 1339125	69,915,000
	-	-	-		US \$ 1339125	69,915,000

- (b) As of the Balance sheet date, the Company's net foreign currency exposure that is not hedged by a derivative instrument or otherwise is Rs. 170,637,842 (Previous Year Rs.185,387,624)
15. (a) In context with the Interim Dividend of Rs.27,840,000 paid by the Company, the Company has not complied with the provisions of section 205(1A) (i.e. there is a delay in transfer of dividend into a separate Bank Account) and 205A (i.e. there is a delay in payment of dividend to its shareholders) of the Companies Act, 1956.
- (b) During the financial year 2009-2010, the Company has paid Remuneration to Ritesh B. Shah, which is in excess of limit specified in section 314(IB) of the Companies Act, 1956. The Company has since recovered the excess remuneration in financial year 2010-11.

16. As per Accounting Standard 15 'Employee Benefits', the disclosures of employee benefits are as under:

Defined Contribution Plan:

Contribution to Defined Contribution Plan recognised as expenses in the Profit and Loss Account for the year ended March 31, 2009:

Particulars	31-3-2010 Rupees	31-3-2009 Rupees
Employer's Contribution to Provident Fund under the Employees Provident Funds and Miscellaneous Provisions Act, 1952	698,200	644,615
	698,200	644,615

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

Defined Benefits Plan:

The present value of obligation is determined based on actuarial valuation using the projected unit credit method. Valuations in respect of gratuity and leave encashment have been carried out and certified by Independent Actuary.

Sr.No.	Particulars	31-03-2010			31-03-2009		
		Gratuity		Leave	Gratuity		Leave
		Unfunded	Funded	Encashment	Unfunded	Funded	Unfunded
(a)	Assumptions:						
	Interest/Discount Rate	8%	8%	8%	7%	7%	7%
	Rate of increase in compensation	4%	4%	10%	4%	4%	10%
	Employee Attrition Rate [Past Service (PS)]:						
	0 to 5	15%	15%	15%	15%	15%	15%
	5 to 10	10%	10%	10%	10%	10%	10%
	10 to 15	5%	5%	5%	5%	5%	5%
	15 to 42	1%	0%	1%	0%	1%	1%
	Expected average remaining service	11.72%	11.33%	11.50%	5.94%	9.27%	8.41%
(b)	Changes in Present Value of Obligation (Rs.):						
	Present value of obligation at beginning of period	167,426	1,209,645	782,177	57,050	956,607	747,147
	Interest cost	11,720	84,675	53,503	4,564	76,529	58,572
	Current service cost	46,930	145,733	301,182	103,628	204,220	362,727
	Benefit paid	–	–	(35,707)	–	–	(30,000)
	Actuarial (gain)/loss on obligation	(12,380)	(142,272)	308,160	2,184	(27,711)	356,269
	Present value of obligation at end of period	213,696	1,297,781	792,995	167,426	1,209,645	782,177
(c)	Change in Fair Value of Plan Assets (Rs.):						
	Fair value of plan assets at beginning of period	–	1,459,026	–	–	1,141,937	–
	Expected return on plan assets	–	135,115	–	–	111,979	–
	Contribution	–	84,510	35,707	–	204,549	30,000
	Benefit paid	–	–	(35,707)	–	–	(30,000)
	Actuarial (gain)/loss on plan assets	–	719	–	–	561	–
	Fair value of plan assets at end of period	–	1,679,370	–	–	1,459,026	–
(d)	Fair Value of Plan Assets (Rs.):						
	Fair value of plan assets at beginning of period	–	1,459,026	–	–	1,141,937	–
	Actual return on plan assets	–	135,834	–	–	112,540	–
	Contributions	–	84,510	35,707	–	204,549	30,000
	Benefit paid	–	–	(35,707)	–	–	(30,000)
	Fair value of plan assets at end of period	–	1,679,370	–	–	1,459,026	–
	Funded Status	(213,696)	381,589	(792,995)	(167,426)	249,381	(782,177)
	Excess of actual over estimated return on plan assets	–	719	–	–	561	–
(e)	Experience History (Rs.):						
	(Gain)/Loss on obligation due to change in assumption	(20,766)	(105,013)	(79,774)	4,188	73,331	64,065
	Experience (Gain)/Loss on obligation	8,386	(37,259)	(228,386)	(2,004)	(101,042)	(420,334)
	Experience (Gain)/Loss on plan assets	–	719	–	–	561	–

SCHEDULES FORMING PART OF ACCOUNTS (Contd.)

Sr.No.	Particulars	31-03-2010			31-03-2009		
		Gratuity		Leave	Gratuity		Leave
		Unfunded	Funded	Encashment	Unfunded	Funded	Unfunded
(f)	Actuarial Gain/(Loss) recognised (Rs.)						
	Actuarial Gain/(Loss) for the period (Obligation)	12,380	142,272	308,160	(2,184)	27,711	356,269
	Actuarial Gain/(Loss) for the period (Plan Assets)	-	719	-	-	561	-
	Total Gain/(Loss) for the period	12,380	142,991	308,160	(2,184)	28,272	356,269
	Actuarial Gain/(Loss) recognised for the period	12,380	142,991	308,160	(2,184)	28,272	356,269
	Unrecognised Actuarial Gain/(Loss) at end of period	-	-	-	-	-	-
(g)	Amount recognised in the Balance Sheet (Rs.):						
	Present value of obligation at end of period	213,696	1,297,781	792,995	167,426	1,209,645	782,177
	Fair value of plan assets at end of period	-	1,679,370	-	-	1,459,026	-
	Funded Status	(213,696)	381,589	(792,995)	(167,426)	249,381	(782,177)
	Unrecognised Actuarial Gain/(Loss)	-	-	-	-	-	-
	Net Assets/(Liability) recognised in the balance sheet	(213,696)	381,589	(792,995)	(167,426)	249,381	(782,177)
(h)	Expenses recognised in the statement of Profit and Loss Account (Rs.):						
	Current service cost	46,930	145,733	301,182	103,628	204,220	362,727
	Interest cost	11,720	84,675	53,503	4,564	76,529	58,572
	Expected return on plan assets	-	(135,115)	-	-	(111,979)	-
	Net Actuarial (Gain)/Loss recognised for the period	(12,380)	(142,991)	(308,160)	2,184	(28,272)	(356,269)
	Expenses recognised in the statement of Profit and Loss Account	46,270	(47,698)	46,525	110,376	140,498	65,030
(i)	Balance Sheet Reconciliation (Rs.):						
	Opening Net Liability	167,426	(249,381)	782,177	57,050	(185,330)	747,147
	Expenses as above	46,270	(47,698)	46,525	110,376	140,498	65,030
	Contribution paid	-	(84,510)	(35,707)	-	(205,549)	(30,000)
	Closing Net Liability	213,696	(381,589)	792,995	167,426	(249,381)	782,177

17. Previous years figures have been re-grouped and/or re-classified as deemed appropriate.

SIGNATURE TO SCHEDULES 1 TO 20

As per our report of even date
For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W

SAMIR S. MOGUL
Partner
Membership No. 100731
Mumbai : August 6, 2010

For **ANUH PHARMA LIMITED**

L. P. SHAH **BIPIN SHAH**
Director Director

Mumbai : August 6, 2010

CASH FLOW STATEMENT

	Rupees	Year 31.03.2010 Rupees	Year 31.03.2009 Rupees
(A) CASH FLOW FROM OPERATING ACTIVITIES:			
Net Profit Before Tax		175,352,515	132,548,472
Adjustment for			
Depreciation	11,582,044		11,224,089
Interest Paid	1,113,755		8,327,899
Other Income	(44,282,469)		(14,465,599)
		<u>(31,586,670)</u>	<u>5,086,389</u>
Operating Profit before Working Capital Changes		143,765,845	137,634,861
Adjustment for			
Trade and Other Receivables	(131,677,101)		117,464,518
Inventories	(40,366,163)		10,846,498
Loans and Advances	(23,053,304)		(2,460,895)
Trade Payables, Other Liabilities and Provisions	164,860,699		(149,572,283)
		<u>(30,235,869)</u>	<u>(23,722,162)</u>
Cash Generated from Operations		113,529,975	113,912,699
Direct Taxes (paid)/refund received		(49,844,016)	(36,464,421)
Net Cash from Operations		63,685,959	77,448,278
(B) CASH FLOW FROM INVESTING ACTIVITIES:			
(Purchase)/Sale of Investments (net)	12,512,943		24,588,479
(Purchase)/Sale of Fixed Assets (net)	(9,953,614)		(17,034,249)
Other Income received	15,576,914		7,767,251
Net Cash used in Investing Activities		18,136,243	15,321,481
(C) CASH FLOW FROM FINANCING ACTIVITIES:			
Total proceeds from Borrowings (net of repayments):			
Secured Loans	25,784,689		(17,826,661)
Interest Paid	(1,113,755)		(8,327,899)
Dividend paid (including tax thereon)	(69,615,704)		(25,716,245)
Net Cash used in Financing Activities		(44,944,770)	(51,870,805)
		<u>36,877,432</u>	<u>40,898,954</u>
INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS (A + B + C)		36,877,432	40,898,953
CASH AND CASH EQUIVALENTS:			
Opening Balance		76,774,768	35,875,815
Closing Balance		113,652,200	76,774,768

- Notes :
- 1 Cash and Cash Equivalents include Cash and Bank Balances as per the Balance Sheet.
 - 2 The Cash Flow Statement has been prepared under the Indirect Method as set out in Accounting Standard 3 'Cash Flow Statements'.
 - 3 Previous year's figures have been regrouped and/or reclassified, wherever deemed necessary.

As per our report of even date
For **S. I. MOGUL & CO.**
Chartered Accountants
Firm Registration No. 106512W

For **ANUH PHARMA LIMITED**

SAMIR S. MOGUL
Partner
Membership No. 100731
Mumbai : August 6, 2010

L. P. SHAH **BIPIN SHAH**
Director Director

Mumbai : August 6, 2010

STATEMENT PURSUANT TO PART IV OF SCHEDULE VI TO THE COMPANIES ACT, 1956.

BALANCE SHEET ABSTRACT AND COMPANY'S GENERAL BUSINESS PROFILE

I. Registration Details			
Registration No.	U 2 4 2 3 0 M H 1 9 6 0 P L C 0 1 1 5 8 6	State Code	1 1
Balance Sheet Date	3 1 0 3 2 0 1 0		
II. Capital Raised during the year:			
Public Issue	N I L	Rights Issue	N I L
Bonus Issue	N I L	Private Placement	N I L
III. Position of Mobilisation and Deployment of Funds:			
Total Liabilities	1 1 0 0 9 7 1 6 8 6	Total Assets	1 1 0 0 9 7 1 6 8 6
Sources of Funds			
Paid-up Capital	1 3 9 2 0 0 0 0	Reserves & Surplus	5 2 4 1 3 8 7 0 6
Secured Loans	N I L	Unsecured Loans	N I L
Deferred Tax Liability (Net)	6 8 2 9 4 1		
Application of Funds			
Net Fixed Assets	9 0 2 3 4 5 1 2	Investments	2 5 7 2 4 9 2 3 2
Net Current Assets	2 2 1 3 1 9 0 9 7	Misc. Expenditure	N I L
Accumulated Losses	N I L	Deferred Tax Asset (Net)	N I L
IV. Performance of Company:			
Turnover (Gross Revenue)	1 7 4 6 8 0 1 0 6 2	Total Expenditure	1 5 5 6 8 2 0 4 3 3
+ - Profit / (Loss) Before Tax	+ 1 7 5 3 5 2 5 1 5	+ - Profit / (Loss) After Tax	+ 1 2 5 4 6 5 7 4 1
Earning Per Share in Rs.	4 5 . 0 7	Dividend rate %	2 0 0
V. Generic Name of Three Principal Products / Services of Company (as per monetary terms):			
Item Code No. (ITC Code)	2 9 4 1 . 5 0		
Product Description	ERYTHROMYCIN SALTS		
Item Code No. (ITC Code)	2 9 4 1 . 4 0		
Product Description	CHLORAMPHENICOL		
Item Code No. (ITC Code)	Not Applicable		
Product Description	Not Applicable		

Note : The above particulars should be read along with the Balance Sheet as at 31st March, 2010, the Profit and Loss Account for the year ended on that date and the schedules forming part thereof.

For **ANUH PHARMA LTD.**

L. P. SHAH
Director

BIPIN SHAH
Director

Mumbai : August 6, 2010.

Certificates of Suitability issued by European Directorate for the Quality of Medicines & Healthcare (EDQM)

for ERYTHROMYCIN

 
European Directorate for the
Quality of Medicines & HealthCare
Certification of Substances Division

Certificate of suitability
No. R0-CEP 2005-205-Rev 00

1 Name of the substance:
2 **ERYTHROMYCIN**

3 Name of holder:
4 **ANUH PHARMA LTD**
5 Dr Annie Besant Road
6 A-3 Shivnagar Estate (North Wing), Worli
7 India-400 018 Mumbai

8 Site(s) of production:
9 **ANUH PHARMA LTD (final substance)**
10 E-17/3 & E 17/4 M.I.D.C. Tarapur
11 Tarapur
12 India-401 506 Solapur

13 **NINGXIA QIYUAN PHARMACEUTICAL CO. LTD (leaf intermediate)**
14 N° 1 Giyuan Street
15 Wangyuan Industrial Area
16 China-750101 Yinchuan, Ningxia

17 After examination of the information provided on the manufacturing method and
18 subsequent processes (including purification) for this substance on the site(s) of
19 production mentioned above, we certify that the quality of the substance is suitably
20 controlled by the current version of the monograph **ERYTHROMYCIN** no. 179 of the
21 European Pharmacopoeia, current edition including supplements, only if it is
22 supplemented by the test(s) mentioned below, based on the analytical procedure(s)
23 given in annex.

24 - Test for residual solvents by gas chromatography (Annex 1)
25 Methylene chloride not more than 500 ppm

26 In the last steps of the synthesis water is used as solvent.

27 The re-latest period of the substance is 3 years if stored in double polyethylene bags.

28 The holder of the certificate has declared the absence of use of material of human or
29 animal origin in the manufacture of the substance.

Address: 1, allée Kalan, CS 39028 - F - 47061 Besençon (France)
Telephone: 33 (0) 1 84 41 39 38 - Fax: 33 (0) 1 84 41 27 71 - e-mail: ceq@edqm.eu
Internet: <http://www.edqm.eu>



for CLOBETASOL PROPIONATE

 
European Directorate for the
Quality of Medicines & HealthCare
Certification of Substances Division

Certificate of suitability
No. R0-CEP 2005-172-Rev 00

1 Name of the substance:
2 **CLOBETASOL PROPIONATE**

3 Name of holder:
4 **ANUH PHARMA LTD**
5 3-A, Shivnagar Estate, North Wing
6 Dr Annie Besant Road, Worli
7 India-400 018 Mumbai, Maharashtra

8 Site(s) of production:
9 **ANUH PHARMA LTD**
10 D-6/8, TTC Industrial Area, M.I.D.C., Turbhe
11 India-400 705 Navi Mumbai, Maharashtra

12 After examination of the information provided on the manufacturing method and
13 subsequent processes (including purification) for this substance on the site(s) of
14 production mentioned above, we certify that the quality of the substance is suitably
15 controlled by the current version of the monograph **CLOBETASOL PROPIONATE** no.
16 2127 of the European Pharmacopoeia, current edition including supplements, only if it is
17 supplemented by the test(s) mentioned below, based on the analytical procedure(s)
18 given in annex.

19 - Test for residual solvents by gas chromatography (Annex 1)
20 Methanol not more than 2000 ppm
21 Chloroform not more than 60 ppm
22 Methylene chloride not more than 600 ppm

23 The holder of the certificate has declared the absence of use of material of human or
24 animal origin in the manufacture of the substance.

25 The submitted dossier must be updated after any significant change that may alter the
26 quality, safety or efficacy of the substance.

27 Manufacture of the substance shall take place in accordance with the Good
28 Manufacturing Practices and in accordance with the dossier submitted.

Address: 1, allée Kalan, CS 39028 - F - 47061 Besençon (France)
Telephone: 33 (0) 1 84 41 39 38 - Fax: 33 (0) 1 84 41 27 71 - e-mail: ceq@edqm.eu
Internet: <http://www.edqm.eu>



for PYRAZINAMIDE

 
European Directorate for the
Quality of Medicines & HealthCare
Certification of Substances Division

Certificate of suitability
No. R0-CEP 2005-059-Rev 00

1 Name of the substance:
2 **PYRAZINAMIDE**

3 Name of holder:
4 **ANUH PHARMA LTD**
5 Mehta Mahal
6 15, Mathew Road, Opera House
7 India-400 004 Mumbai, Maharashtra

8 Site(s) of production:
9 **ANUH PHARMA LTD**
10 E-17/3 & E 17/4 M.I.D.C.
11 Tarapur, Thane District
12 India-401 506 Solapur, Maharashtra

13 After examination of the information provided on the manufacturing method and
14 subsequent processes (including purification) for this substance on the site(s) of
15 production mentioned above, we certify that the quality of the substance is suitably
16 controlled by the current version of the monograph **PYRAZINAMIDE** no. 859 of the
17 European Pharmacopoeia, current edition including supplements, only if it is
18 supplemented by the test(s) mentioned below, based on the analytical procedure(s)
19 given in annex.

20 - Test for related substances by liquid chromatography (Annex 1)
21 Any other detectable impurity * not more than 0.05%
22 *other than those mentioned in the monograph

23 In the last steps of the synthesis water is used as solvent.

24 The holder of the certificate has declared the absence of use of material of human or
25 animal origin in the manufacture of the substance.

26 The submitted dossier must be updated after any significant change that may alter the
27 quality, safety or efficacy of the substance.

Address: 1, allée Kalan, CS 39028 - F - 47061 Besençon (France)
Telephone: 33 (0) 1 84 41 39 38 - Fax: 33 (0) 1 84 41 27 71 - e-mail: ceq@edqm.eu
Internet: <http://www.edqm.eu>



for ERYTHROMYCIN ETHYL SUCCINATE

 
European Directorate for the
Quality of Medicines & HealthCare
Certification of Substances Division

Certificate of suitability
No. R0-CEP 2007-235-Rev 00

1 Name of the substance:
2 **ERYTHROMYCIN ETHYL SUCCINATE**

3 Name of holder:
4 **ANUH PHARMA LTD**
5 3-A, Shivnagar Estate, North Wing
6 Dr Annie Besant Road, Worli
7 India-400 018 Mumbai, Maharashtra

8 Site(s) of production:
9 **ANUH PHARMA LTD**
10 E-17/3 & E 17/4 M.I.D.C.
11 Tarapur, Thane District
12 India-401 506 Solapur, Maharashtra

13 After examination of the information provided on the manufacturing method and
14 subsequent processes (including purification) for this substance on the site(s) of
15 production mentioned above, we certify that the quality of the substance is suitably
16 controlled by the current version of the monograph **ERYTHROMYCIN**
17 **ETHYL SUCCINATE** no. 274 of the European Pharmacopoeia, current edition including
18 supplements, only if it is supplemented by the test(s) mentioned below, based on the
19 analytical procedure(s) given in annex.

20 Any other impurity than those mentioned in the monograph and detected by the test
21 for related substances of the monograph is individually limited to not more than 0.2%.

22 - Test for residual solvents by gas chromatography (Annex 1)
23 Acetone not more than 5000 ppm

24 In the last steps of the synthesis water is used as solvent.

25 The holder of the certificate has declared the absence of use of material of human or
26 animal origin in the manufacture of the substance.

27 The submitted dossier must be updated after any significant change that may alter the
28 quality, safety or efficacy of the substance.

Address: 1, allée Kalan, CS 39028 - F - 47061 Besençon (France)
Telephone: 33 (0) 1 84 41 39 38 - Fax: 33 (0) 1 84 41 27 71 - e-mail: ceq@edqm.eu
Internet: <http://www.edqm.eu>





ANUH PHARMA LIMITED

Registered Office :

3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, Mumbai - 400 018.

ATTENDENCE SLIP

ANUH PHARMA LTD.

Registered office : 3-A, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400 018

PLEASE FILL ATTENDANCE SLIP AND HAND IT OVER AT THE ENTRANCE OF THE MEETING HALL

Joint shareholders may obtain additional slip on request.

NAME AND ADDRESS OF THE SHARE HOLDER

Folio No.

No. of Shares

I hereby record my presence at the FIFTIETH ANNUAL GENERAL MEETING of the company held at M. C. Ghia Hall, 2nd Floor, Bhogilal Hargovinddas Road, 18/20, K. Dubash Marg, Mumbai - 400 001 on **Friday, 17th September, 2010.**

Signature of the Share Holder or the proxy

* Strike out whichever is not applicable.

Tear Here

PROXY FORM

ANUH PHARMA LTD.

Registered office : 3-A, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400 018

Folio No.

I/We _____

of _____ being member /

members of Anuh Pharma Ltd. hereby appoint _____

_____ of _____

or failing him _____ of _____

as my/our proxy to vote for me/us and my/our behalf at the 50th Annual General Meeting to be held on Friday, 17th September, 2010, and at any adjournment thereof.

Signed this _____ day of _____ 2010

Affix a
Re. 1/-
Revenue
Stamp

Note : The proxy in order to be effective be duly stamped completed and signed and must be deposited at the Registered Office of the Company not less than 48 hours before the time of holding the aforesaid Meeting. The proxy need not be a Member of the Company.